2024 SHELTER SAVINGS BOOK

Programs subject to change without notice.

800.225.7911
PATTERSONVET.COM/SHELTER

TRUSTED EXPERTISE.
UNRIVALED SUPPORT.®

PATTERSON® VETERINARY

SHELTER SAVINGS UNDER ONE ROOF

Welcome to Patterson's shelter program.

We know that shelters play a special role in the lives of those in their care. As they gather animals in need under their roof, they accept the challenge of providing medical help, nutrition and socialization to help them thrive.

Patterson Veterinary supports the health and wellness of animals and appreciates how you perform a valuable service for the community. This dedicated program is our way of saying thanks. It offers access to promotions from our manufacturers that are just for 501(c)(3) shelters, humane societies and rescue groups.

We've gathered a range of exclusive shelter promotions into a single program "under one roof" to make them easy to use. Shelter staff can find benefits quickly, place an order and get back to their mission of caring for animals. We hope these benefits help shelters spend less as they provide care that lets their residents live the healthiest lives possible.

If you have questions about any items that are part of the program or savings available to shelters, we're here to help. Visit **pattersonvet.com/shelter** or call us at **800.225.7911**.

TRUSTED EXPERTISE. UNRIVALED SUPPORT.®

TABLE OF CONTENTS



10% OFF ANTIMICROBIALS

BACTERIA, YEAST, & FUNGUS

PHARMASEB

78946373 Pharmaseb Shampoo, Cucumber Melon | 8 oz
78946281 Pharmaseb Shampoo, Cucumber Melon | 16 oz
78946400 Pharmaseb Shampoo, Cucumber Melon | 1 G
78946286 Pharmaseb Mousse, Cucumber Melon | 7 oz
78946284 Pharmaseb Leave-On Spray, Cucumber Melon | 4 oz
78946285 Pharmaseb Leave-On Spray, Cucumber Melon | 8 oz
78946187 Pharmaseb Wipes, Cucumber Melon | 50 ct
78947947 Pharmaseb Keto-C XL Wipes, Cucumber Melon | 60 ct

RESISTANT TO BACTERIA

CHLORHEXIDINE SHAMPOO

78946016 MAX Chlorhexidine 4% Shampoo, Blueberry | 12 oz
78946402 MAX Chlorhexidine 4% Shampoo, Blueberry | 1 G

10% OFF ANTIPRURITICS

ITCHING DUE TO ALLERGIES

HYDROCORTISONE SPRAY

78946280 Hydrocortisone Spray, Unscented | 4 oz

PRAMOX

78946288 Pramox Crème Rinse, Tropical Guava | 16 oz
78946419 Pramox Shampoo, Tropical Guava | 16 oz
78946357 Pramox Spray, Tropical Guava | 8 oz

10% OFF ANTISEBORRHEICS

SEBORRHEA SICCA

BENZOYL PEROXIDE SHAMPOO

78946448 Benzoyl Peroxide Shampoo, Passion Fruit | 12 oz

10% OFF
GROOMING

CLEANING & DEODORIZING

ALOE & OATMEAL

78946430 Aloe & Oatmeal Crème Rinse, Piña Colada | 16 oz
78946290 Aloe & Oatmeal Crème Rinse, Piña Colada | 1 G
78946428 Aloe & Oatmeal Shampoo, Piña Colada | 16 oz
78946429 Aloe & Oatmeal Shampoo, Piña Colada | 1 G

SOAP-FREE SHAMPOO

78946432 Tearless Soap-Free Shampoo, Fruit | 16 oz

EFA HYPOALLERGENIC SHAMPOO

78946291 EFA Hypoallergenic & Deodorizing Shampoo, Sweet Pea Vanilla | 16 oz
78946431 EFA Hypoallergenic & Deodorizing Shampoo, Sweet Pea Vanilla | 1 G

DEODORIZING

BODY SPRAY

78946422 Body Spray, Cherry Blossom | 8 oz
78946289 Body Spray, Cucumber Melon | 8 oz
78946424 Body Spray, Sugar Cookie | 8 oz
78946427 Body Spray, Sweet Pea Vanilla | 8 oz

WHITENING

PEARLYBRITE SHAMPOO

78946420 Pearlybrite Whitening Shampoo, Piña Colada | 12 oz
78946421 Pearlybrite Whitening Shampoo, Piña Colada | 1 G

10% OFF
OTIC

ANTIMICROBIAL, REDUCE YEAST

KETOMAX FLUSH

78946302 Ketomax Tris Flush | 8 oz

PHARMASEB FLUSH

78946282 Pharmaseb Flush | 4 oz
78946283 Pharmaseb Flush | 8 oz

EAR FLUSH

78946303 Ear Flush Otic Solution, Cherry Blossom | 8 oz
78946423 Ear Flush Otic Solution, Cucumber Melon | 8 oz
78946399 Ear Flush Otic Solution, Cucumber Melon | 1 G
78946401 Ear Flush Otic Solution, Eucalyptus | 8 oz
78946425 Ear Flush Otic Solution, Sugar Cookie | 8 oz
78946426 Ear Flush Otic Solution, Sweet Pea Vanilla | 8 oz

** Offer applies to practicing veterinarians only. Animal Pharmaceuticals reserves the right to change, cancel, or refuse this program at any time. Cannot be combined with any other discounts, promotions, or programs.*

Aspen Veterinary Resources
2024 Shelter Programs

January 1 - December 31, 2024

Aspen Veterinary Resources' Shelter Program is an exclusive offer for qualifying customers, including zoos, wildlife refuges, animal shelters, and humane societies. Discount will be applied upon verification of 501(c)(3) qualification. No limit.

EVERYDAY ESSENTIALS | 7% OFF!

OFFER	PRODUCT NAME	MPN
	Bismusal® Suspension, Gallon	21258847
	Bismusol Suspension, Gallon	13948574
	Chloradine® Scrub 2%, Gallon	19976005
	Chloradine® Scrub 4%, Gallon	10966005
	Chlorhexidine Solution 2%, Gallon	11584915
	Fly Zap® Aerosol Plus, 20 oz	21270934
	Fly Zap® Aerosol Plus, 25 oz	21270935
	Fly Zap® Indoor Fogger, 6.5 oz	21272665
	General Lube +1 Pump, Gallon (4/Case)	21273372
	Hydrogen Peroxide 3%, Gallon	17214830
	Kaolin Pectin Suspension, Gallon	12506179
	Mineral Oil, USP, Gallon	21263351
	Topical Fungicide +Sprayer, 32 oz	15689634
	Triodine-7, Gallon	16513456

COHESIVE BANDAGES | 20% OFF!

OFFER	PRODUCT NAME	MPN
	Flexwrap® E-Z Tear® 4" Assorted 18s	14100122
	Flexwrap® E-Z Tear® 4" Black 18s	12585822
	Flexwrap® E-Z Tear® 4" Blue 18s	12588965
	Flexwrap® E-Z Tear® 4" Hunter Green 18s	17357754
	Flexwrap® E-Z Tear® 4" Lime Green 18s	14455876
	Flexwrap® E-Z Tear® 4" Pink 18s	19665756
	Flexwrap® E-Z Tear® 4" Purple 18s	18568564
	Flexwrap® E-Z Tear® 4" Red 18s	14654687
	Flexwrap® E-Z Tear® 4" White 18s	11169935

Offer applies to practicing veterinarians only. Aspen Veterinary Resources, LTD., reserves the right to change, cancel, or refuse this program at any time. Cannot be combined with any other discounts, promotions, or programs. Offer valid January 1 – December 31, 2024.

OFFER	PRODUCT NAME	MPN
ECONOMY SUTURE | 7% OFF!	eco-Lon™ Nylon, Blue, 4-0, 30", FS-2, Reverse Cutting, 3/8c, 19 mm | 12s	21293177
	eco-Lon™ Nylon, Blue, 3-0, 30", FS-1, Reverse Cutting, 3/8c, 24 mm | 12s	21293178
	eco-Lon™ Nylon, Blue, 2-0, 30", Fs, Reverse Cutting, 3/8c, 26 mm | 12s	21293179
	eco-Max™ PDO, Violet, 4-0, 30", SH, Taper Point, 1/2c, 26 mm | 12s	21293290
	eco-Max™ PDO, Violet, 3-0, 30", SH, Taper Point, 1/2c, 26 mm | 12s	21293291
	eco-Max™ PDO, Violet, 2-0, 30", SH, Taper Point, 1/2c, 26 mm | 12s	21293292
	eco-Max™ PDO, Violet, 3-0, 30", CT-2, Taper Point, 1/2c, 26 mm | 12s	21293293
	eco-Max™ PDO, Violet, 2-0, 30", CT-2, Taper Point, 1/2c, 26 mm | 12s	21293294
	eco-Max™ PDO, Violet, 0, 30", CT-2, Taper Point, 1/2c, 26 mm | 12s	21293295
	eco-Max™ PDO, Violet, 2-0, 30", CT-1, Taper Point, 1/2c, 36 mm | 12s	21293296
	eco-Max™ PDO, Violet, 0, 30", CT-1, Taper Point, 1/2c, 36 mm | 12s	21293297
	eco-Max™ PDO, Violet, 4-0, 30", FS-2, Reverse Cutting, 3/8c, 19 mm | 12s	21293298
	eco-Max™ PDO, Violet, 3-0, 30", FS-2, Reverse Cutting, 3/8c, 19 mm | 12s	21293299
	eco-Max™ PDO, Violet, 2-0, 30", FS-1, Reverse Cutting, 3/8c, 24 mm | 12s	21293300
	eco-Max™ PDO, Violet, 3-0, 30", FS-1, Reverse Cutting, 3/8c, 24 mm | 12s	21293301
	eco-Max™ PDO, Violet, 2-0, 30", CP-1, Reverse Cutting, 1/2c, 36 mm | 12s	21293302
	eco-Max™ PDO, Violet, 0, 30", CP-1, Reverse Cutting, 1/2c, 36 mm | 12s	21293303
	eco-Max™ PDO, Violet, 1, 30", CP-1, Reverse Cutting, 1/2c, 36 mm | 12s	21293304
	eco-Max™ PDO, Violet, 2-0, 30", CP-2, Reverse Cutting, 1/2c, 26 mm | 12s	21293306

OFFER	PRODUCT NAME	MPN
ECONOMY SUTURE | 7% OFF!	eco-Max™ PDO, Violet, 0, 30", CP-2, Reverse Cutting, 1/2c, 26 mm | 12s	21293307
	eco-Web™ PGCL, Violet, 3-0, 30", SH, Taper Point, 1/2c, 26 mm | 12s	21293309
	eco-Web™ PGCL, Violet, 3-0, 36", CT-1, Taper Point, 1/2c, 36 mm | 12s	21293310
	eco-Web™ PGCL, Violet, 2-0, 36", CT-1, Taper Point, 1/2c, 36 mm | 12s	21293311
	eco-Web™ PGCL, Violet, 4-0, 36", FS-2, Reverse Cutting, 3/8c, 19 mm | 12s	21293312
	eco-Web™ PGCL, Violet, 3-0, 36", FS-2, Reverse Cutting, 3/8c, 19 mm | 12s	21293313
	eco-Web™ PGCL, Violet, 3-0, 36", FS-1, Reverse Cutting, 3/8c, 24 mm | 12s	21293314
	eco-Web™ PGCL, Violet, 2-0, 36", FS-1, Reverse Cutting, 3/8c, 24 mm | 12s	21293315
	eco-Web™ PGCL, Violet, 0, 36", CP-1, Reverse Cutting, 1/2c, 36 mm | 12s	21293316
	eco-Web™ PGCL, Violet, 0, 36", FSL, Reverse Cutting, 3/8c, 30 mm | 12s	21293317
	eco-Cryl™ PGLA, Violet, 3-0, 30", CT-2, Taper Point, 1/2c, 26 mm | 12s	21293321
	eco-Cryl™ PGLA, Violet, 2-0, 30", CT-2, Taper Point, 1/2c, 26 mm | 12s	21293322
	eco-Cryl™ PGLA, Violet, 2-0, 30", CT-1, Taper Point, 1/2c, 36 mm | 12s	21293324
	eco-Cryl™ PGLA, Violet, 4-0, 30", FS-2, Reverse Cutting, 3/8c, 19 mm | 12s	21293327
	eco-Cryl™ PGLA, Violet, 3-0, 30", FS-2, Reverse Cutting, 3/8c, 19 mm | 12s	21293328
	eco-Cryl™ PGLA, Violet, 3-0, 30", FS-1, Reverse Cutting, 3/8c, 24 mm | 12s	21293329
	eco-Cryl™ PGLA, Violet, 2-0, 30", FS-1, Reverse Cutting, 3/8c, 24 mm | 12s	21293330
	eco-Cryl™ PGLA, Violet, 0, 30", CP-1, Reverse Cutting, 1/2c, 36 mm | 12s	21293334
	eco-Cryl™ PGLA, Violet, 0, 30", FSL, Reverse Cutting, 3/8c, 30 mm | 12s	21293338

Offer applies to practicing veterinarians only. Aspen Veterinary Resources, LTD., reserves the right to change, cancel, or refuse this program at any time. Cannot be combined with any other discounts, promotions, or programs. Offer valid January 1 – December 31, 2024.

2023 Shelter Agreement

These offers have been **extended through 2024!**

For 501(c) (3) Non-Profit Organizations, Humane Societies, and Animal Rescues

Shelter Agreement Benefits:

BUY 1 GET 1 FREE

Vectra® for Dogs and Puppies

Vectra® for Cats and Kittens

Vectra® 3D for Dogs

Catego® for Cats

MilbeGuard® (milbemycin oxime) Flavored Tablets

IMECTRO® Chew (ivermectin/pyrantel pamoate/praziquantel)

CEVAsaves™

Terms and Conditions:
Customers participating in this program are not eligible for any other promotions or rebates on products covered by this agreement.
Customers must show proof of 502 (c) (3) status. New Customers require a minimum purchase of $1,000.00 to be enrolled in the program
Ceva reserves the right to vary the terms and conditions of these promotions or cancel these promotions at any time without notice.

VETIGEL®

Non-Profit Program

BUY 2 GET 1
COMPLIMENTARY

Buy 2 on a single invoice, get 1 complimentary. The offer is mix and match and cannot be combined with any other offers. Complimentary good to be least expensive item purchased. Please complete survey to receive complimentary goods. Vendor (VETIGEL) ships complimentary goods.

Scan the QR code to complete the survey and receive the complimentary goods.


PAWS 4 PURPOSE™
ADVANCING
THE HEALTH AND
WELL-BEING OF
ANIMALS IN NEED
Elanco

Customers first, animals always

Animal health is our heritage

Throughout our 65-year history, Elanco Animal Health has both served and partnered with animal health industry professionals around the world. Animals in more than 90 countries have benefitted from our products and services to prevent and treat disease. Elanco is always searching for ways to improve pets' lives, as demonstrated by developing multiple innovations in parasiticides and 1/2 mL vaccines for the companion animal market.

Elanco's global presence allows us to play a crucial role in fulfilling our ultimate purpose of creating a healthier world. At the same time, we also care deeply about the companion animals in our own backyard and the people who provide for them. That's why we created the **Paws 4 Purpose** program as part of our Healthy Purpose™ framework.

Our Vision: Food and companionship enriching life

Our History: 65-year legacy of commitment to animal health and well-being

Our Promise: Rigorous innovation to benefit our customers and improve the health of animals

Our Healthy Purpose™: Advance the well-being of animals, people and the planet

- **Paws 4 Purpose**: Animal welfare framework focused on the well-being of animals in need

Elanco's HEALTHY PURPOSE™

Healthier Animals

Helping pets and food animals live healthy, quality lives by continuously **identifying new and innovative animal care products and practices**, while sharing our expertise.

Healthier People

Improving people's health, lives and livelihoods by **promoting animal companionship** and enabling sustainable production of meat, milk, fish and eggs.

Healthier Planet

Conserving natural resources by **leveraging innovations and technological advances** that will help our stakeholders produce more food, while making ourselves responsible stewards of our environment.

Healthier Enterprise

Managing our own environmental footprint and governing our business with the **highest ethical standards** while creating an environment where all employees feel safe, respected, empowered and invested in making a difference to society.

Your mission is our mission

At Elanco, we believe animals can be a solution to some of our world's greatest challenges. Companion animals like dogs and cats in particular have a positive impact on society through the human-animal bond.

Nowhere is this human-animal connection felt more strongly than in animal welfare organizations. Many animals who would otherwise go without care receive everything from basic necessities to their forever homes through the dedication of people like you.

How our missions align

ANIMAL WELFARE ORGANIZATIONS

MEET THE **PHYSICAL, EMOTIONAL & HEALTHCARE** NEEDS OF ANIMALS

HELP PLACE ANIMALS WITH A **SUITABLE PET PARENT** AND RESCUE ANIMALS IN DISTRESS

HELP BUILD COMMUNITY SUPPORT FOR THE HUMANE, ETHICAL TREATMENT OF ANIMALS

PROVIDE **VOLUNTEER** AND **EMPLOYMENT OPPORTUNITIES** FOR COMMUNITY MEMBERS

ELANCO ANIMAL HEALTH

HAS PROVIDED AID FOR THE TRAINING AND REGISTRATION OF MORE THAN **11,000 PET PARTNERS™ HANDLERS ACROSS NINE THERAPY ANIMAL SPECIES**

HAS HELPED **EXPAND ANIMAL THERAPY WORK IN 11 COUNTRIES** TO REGISTER PET PARTNERS™ TRAINERS AND TEAMS

HAS INVESTED IN **KEY RESEARCH GAPS** IN THE HUMAN-ANIMAL BOND, IN ORDER TO DEMONSTRATE PETS' VALUE TO SOCIETY

HAS COMPLETED 10,000+ SERVICE HOURS ON OUR 2018 GLOBAL DAY OF PURPOSE, POSITIVELY IMPACTING THE WORLD AND LOCAL COMMUNITIES

Did you know?

ELANCO HAS WORKED WITH MORE THAN **2,000 ANIMAL WELFARE ORGANIZATIONS.**

Benefits of the PAWS 4 PURPOSE™ *program*

Helping You Help Animals

Elanco understands the necessity of and the compassion that goes into the work you do. We also understand that it can be challenging to provide the level of care necessary to keep animals happy and healthy.

Participating in the Paws 4 Purpose program is an easy way to help your organization reach and maintain the high standards of disease prevention, diagnosis and treatment outlined in the Five Freedoms For Animal Welfare. The Five Freedoms were used as the basis for official animal welfare guidelines developed by the Association of Shelter Veterinarians (ASV).[1]

Five Freedoms for Animal Welfare

1. Freedom from Hunger and Thirst by ready access to fresh water and a diet to maintain full health and vigor
2. Freedom from Discomfort by providing an appropriate environment including shelter and a comfortable resting area
3. **Freedom from Pain, Injury or Disease by prevention or rapid diagnosis and treatment**
4. Freedom to Express Normal Behavior by providing sufficient space, proper facilities and company of the animal's own kind
5. Freedom from Fear and Distress by ensuring conditions and treatment which avoid mental suffering

Ask us how to participate in Paws 4 Purpose

For more information on Elanco's Paws 4 Purpose program, as well as product and pricing information, please contact your Elanco Sales Representative.

Benefits

Support from Our Staff

Elanco places the highest value on the partnership with our customers. We will be your advocate and earn your trust by:

- Providing scientific and practical expertise, quality products and best-in-class service
- Being available, accessible and attuned to the needs and goals of your organization

Elanco's Pet Pledge

We will strive to improve the world's wellbeing by helping at least 100 million more healthy pets help people.

Training Resources

When it comes to disease prevention, it's important to practice good hygiene protocol, as well as to administer the right products in the right way. Elanco offers a variety of training opportunities to help you, your staff and volunteers with the everyday challenges you face as an animal welfare organization. We can provide the tools, resources and expertise needed to discuss many different areas of interest.

Vaccine Safety and Efficacy — What to expect with vaccines used in shelter situations, including a review of appropriate handling and storage.

Canine Infectious Respiratory Disease Prevention — Review of the causes, transmission and prevention of Canine Infectious Respiratory Disease (CIRD).

Vaccination Strategies in Shelters — Discuss intake strategies and wellness protocols, vaccination strategies for CIRD, leptospirosis and calicivirus, as well as core vs. non-core vaccines.

Infectious Disease Control — Review which areas of the shelters are at risk for transferring disease, and discuss how vaccination and biological risk management can work together to prevent disease.

Parasitology — Provide an overview of heartworm, flea, tick and intestinal parasite discussions. Review lifecycles, diagnostics and clinical signs

myElanco.com

myElanco is a digital tool you can rely on for the resources you need - from treating and protecting your patients to taking care of your own people and optimizing your business. You'll have access to on-demand continuing education courses (with automatic credit transfers).



Trusted, Quality Products

Elanco products are designed to meet the healthcare needs of animals you and your staff care for, many of which have been used and trusted by veterinarians for years. Available products are outlined in the following pages.

Did you know?

Training and continuing education through the Paws 4 Purpose program can help staff stay aligned with guidelines from the ASV, which require employees and volunteers to complete training before beginning a new task.

Featured Elanco Products

Vaccinations are an integral component of any animal welfare organization's overall health program. Elanco has a broad range of vaccine options to meet both your intake and wellness needs, including modified live and inactivated vaccines.

Canine Vaccines

BRAND	INDICATION
truCan	Convenient combinations for safe, effective protection against distemper, adenovirus, parainfluenza, parvovirus, leptospirosis and Lyme disease
Rabvac	One-year and three-year rabies protection for dogs and cats
truCan BAPi (IN)	Intranasal protection against *Bordetella bronchiseptica*, parainfluenza and adenovirus type-2
truCan DAPPi+L4	Four-way leptospirosis protection against today's most common serovars, *L. grippotyphosa* and *L. pomona* as well as *L. icterohaemorrhagiae* and *L. canicola*
PUREFIL TECHNOLOGY	Highly-purified ½ mL vaccines made with PureFil™ Technology, designed to minimize reactions associated with unwanted proteins and debris and to reduce discomfort

Feline Vaccines

BRAND	INDICATION
truFel	Combinations for core antigens, including a non-adjuvanted option (Fel-O-Guard® Plus 3) Vaccines to fight calicivirus, leukemia, herpesvirus and panleukopenia Exclusive dual-strain calicivirus protection
Intranasal FVRC	Intranasal 0.2 mL FVRC and FVRCP vaccines
Rabvac	One-year and three-year rabies protection for dogs and cats
truFel ultra	Includes the only lower volume FVRCP-FeLV combination with exclusive dual-strain calicivirus protection
truFel ultra HC2P hybrid	Non-adjuvanted ½ mL Exclusive dual-strain calicivirus protection

Our Regional Veterinary Consultants would be happy to discuss protocol options to meet your specific needs.



FEAR FREE
Taking the pet out of petrified.

Proud Fear Free partner

As part of our partnership with Fear Free, Elanco supports their mission to help veterinarians and animal welfare organizations reduce stress in pets. We also offer vaccines that allow veterinary professionals to provide Fear Free experiences to their patients.

Register for the Fear Free Shelters program at FearFreeShelters.com — available free to all shelter, rescue, and animal welfare employees and volunteers.

Products Included in Paws 4 Purpose Program:

Advantage® II

advantage multi® (imidacloprid+moxidectin)

Atopica® (cyclosporine capsules) USP MODIFIED

Atopica® for Cats (cyclosporine oral solution) USP MODIFIED

Bexacat™ (bexagliflozin tablets)
Before using Bexacat, it is important to read the entire package insert including the **boxed warning.**

Canine Parvovirus Monoclonal Antibody

Cheristin® for cats spinetoram

CLARO® (florfenicol, terbinafine, mometasone furoate) Otic Solution

Comfortis® (spinosad)

Credelio® (lotilaner)

Credelio® CAT (lotilaner)

Deramaxx® (deracoxib)

Tablets and Injectable Droncit® (praziquantel)

Tablets Drontal® (praziquantel/pyrantel pamoate)

Drontal® Plus (praziquantel/pyrantel pamoate/febantel)

Taste Tabs® Drontal® Plus (praziquantel/pyrantel pamoate/febantel)

Elura™ (capromorelin oral solution)

Entyce® (capromorelin oral solution)

Galliprant® (grapiprant tablets)

Interceptor® (milbemycin oxime)

INTERCEPTOR® PLUS (milbemycin oxime/praziquantel)

K9 Advantix® II

onsior® (robenacoxib)

Topical Solution profender® (emodepside/praziquantel)

quellin® (carprofen) soft chewable tablets

Seresto®

Surolan® (miconazole nitrate, polymyxin B sulfate, prednisolone acetate)

Trifexis® (spinosad+milbemycin oxime)

truCan™

truFel™

Veraflox® (pradofloxacin) Oral Suspension for Cats

Zorbium® (buprenorphine transdermal solution)
Before using Zorbium, it is important to read the entire package insert including the **boxed human warning.**

Ask us how to participate in Paws 4 Purpose

For more information on Elanco's Paws 4 Purpose program, as well as product and pricing information, please contact your Elanco Sales Representative.

Scan here for the advantage multi® for dogs label

Scan here for the Bexacat™ label

Scan here for the Zorbium® label

Bexacat Indication:
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

Bexacat Important Safety Information:
Before using Bexacat, you must read the entire package insert, including the boxed warning. Call 1-888-545-5973 or visit https://www.elancolabels.com/us/bexacat for complete safety information. Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat. Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, diarrhea that is unresponsive to conventional therapy, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level. Bexacat should not be initiated in cats with pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function. Consult a physician in case of accidental ingestion by humans. For complete directions for use and safety information see product label.

Before using ZORBIUM (buprenorphine transdermal solution), read the entire package insert including the Boxed Human Warning. Call 1-888-545-5973 for full prescribing information. For complete directions for use and safety information see product label .

PAWS 4 PURPOSE™



Elanco

[1]ASPCA Guiding Principles 2023 (v1.0). Available at: https://www.aspca.org/about-us/aspca-policy-and-position-statements/guiding-principles. Accessed Dec 18, 2023.

Elanco™

advantage multi™ for dogs

(imidacloprid+moxidectin)
Topical Solution

Once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, kills adult fleas, is indicated for the treatment of flea infestations, the treatment and control of sarcoptic mange, as well as the treatment and control of intestinal parasite infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

WARNING
- **DO NOT ADMINISTER THIS PRODUCT ORALLY**
- **For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.**
- **Children should not come in contact with application sites for two (2) hours after application.**

(See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information)

CAUTION:
Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:
Advantage Multi for Dogs (10 % imidacloprid + 2.5 % moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of dogs. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin based on body weight.

Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name for imidacloprid is 1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete *Streptomycetes cyaneogriseus noncyanogenus*. The chemical name for moxidectin is [6R, 23E, 25S(E)]-5-O- Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

INDICATIONS:
Advantage Multi for Dogs is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* and the treatment of *Dirofilaria immitis* circulating microfilariae in heartworm-positive dogs. *Advantage Multi for Dogs* kills adult fleas and is indicated for the treatment of flea infestations (*Ctenocephalides felis*). *Advantage Multi for Dogs* is indicated for the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei* var. *canis*. *Advantage Multi for Dogs* is also indicated for the treatment and control of the following intestinal parasites:

Intestinal Parasite		Intestinal Stage		
		Adult	Immature Adult	Fourth Stage Larvae
Hookworm Species	*Ancylostoma caninum*	X	X	X
	Uncinaria stenocephala	X	X	X
Roundworm Species	*Toxocara canis*	X		X
	Toxascaris leonina	X		
Whipworm	*Trichuris vulpis*	X		

DOSAGE AND ADMINISTRATION:
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.

1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the *Advantage Multi for Dogs* tube that correctly corresponds with the body weight of the dog.

Dog (lbs.)	Advantage Multi For Dogs	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)
3–9	*Advantage Multi 9*	0.4	40	10
9.1–20	*Advantage Multi 20*	1.0	100	25
20.1–55	*Advantage Multi 55*	2.5	250	62.5
55.1–88	*Advantage Multi 88*	4.0	400	100
88.1–110*	*Advantage Multi 110*	5.0	500	125

* Dogs over 110 lbs. should be treated with the appropriate combination of *Advantage Multi for Dogs* tubes.



2. While holding the tube in an upright position, remove the cap from the tube.
3. Turn the cap over and push the other end of cap onto the tip of the tube.
4. Twist the cap to break the seal and then remove cap from the tube.





5. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog.

Do not let this product get in your dog's mouth or eyes. **Do not allow the dog to lick any of the application sites for 30 minutes.** In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites.
(See WARNINGS.) Contact with eyes can lead to eye irritation and corneal ulceration. If contact with eyes occurs, hold the dog's eyelids open, flush thoroughly with water, and contact your veterinarian.

Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product.

Shampooing 90 minutes after treatment does not reduce the effectiveness of *Advantage Multi for Dogs* in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of *Advantage Multi for Dogs* in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

Heartworm Prevention: For prevention of heartworm disease, *Advantage Multi for Dogs* should be administered at one-month intervals. *Advantage Multi for Dogs* may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer *Advantage Multi for Dogs* immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with *Advantage Multi for Dogs* should be given within one month of the last dose of the former medication.

Treatment of Circulating Microfilaria: For the treatment of circulating *D. immitis* microfilaria in heartworm-positive dogs, *Advantage Multi for Dogs* should be administered at one-month intervals. Treatment with an approved adulticide therapy is recommended because *Advantage Multi for Dogs* is not effective for the treatment of adult *D. immitis*.
(See PRECAUTIONS.)

Flea Treatment: For the treatment of flea infestations, *Advantage Multi for Dogs* should be administered at one-month intervals. If the dog is already infested with fleas when the first dose of *Advantage Multi for Dogs* is administered, adult fleas on the dog will be killed. However, reinfestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Dogs treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the dog.

Treatment and Control of Intestinal Nematode Infections: For the treatment and control of intestinal hookworm infections caused by *Ancylostoma caninum* and *Uncinaria stenocephala* (adults, immature adults and fourth stage larvae) and roundworm infections caused by *Toxocara canis* (adults and fourth stage larvae), and *Toxascaris leonina* (adults), and whipworm infections caused by *Trichuris vulpis* (adults), *Advantage Multi for Dogs* should be administered once as a single topical dose.

Treatment and Control of Sarcoptic Mange: For the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei* var. *canis*, *Advantage Multi for Dogs* should be administered as a single topical dose. A second monthly dose may be administered if necessary.

CONTRAINDICATIONS:
Do not administer this product orally. (See WARNINGS.)
Do not use this product (containing 2.5 % moxidectin) on cats.

WARNINGS
For the first 30 minutes after application:
Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs, and
Separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion.
Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.
In avermectin sensitive dogs,[a] the signs may be more severe and may include coma and death.[b]

[a] Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.

[b] Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care.

HUMAN WARNINGS:

Not for human use. Keep out of the reach of children.
Children should not come in contact with application sites for two (2) hours after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. **Wash hands thoroughly with soap and warm water after handling.**

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For product questions, to report adverse reactions, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973.

PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information.

Use with caution in sick, debilitated, or underweight animals. The safety of *Advantage Multi for Dogs* has not been established in breeding, pregnant, or lactating dogs. The safe use of *Advantage Multi for Dogs* has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.

Prior to administration of *Advantage Multi for Dogs*, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of *Advantage Multi for Dogs* has not been evaluated when administered on the same day as an adulticide. *Advantage Multi for Dogs* is not effective against adult *D. immitis*. Although the number of circulating microfilariae is substantially reduced in most dogs following treatment with *Advantage Multi for Dogs*, the microfilaria count in some heartworm-positive dogs may increase or remain unchanged following treatment with *Advantage Multi for Dogs* alone or in a dosing regimen with melarsomine dihydrochloride.
(See ADVERSE REACTIONS and ANIMAL SAFETY – Safety Study in Heartworm-Positive Dogs.)

Advantage Multi for Dogs has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease.

ADVERSE REACTIONS:

Heartworm-Negative Dogs

Field Studies: Following treatment with *Advantage Multi for Dogs* or an active control, dog owners reported the following post-treatment reactions:

OBSERVATION	Advantage Multi n = 128	Active Control n = 68
Pruritus	19 dogs (14.8%)	7 dogs (10.3%)
Residue	9 dogs (7.0%)	5 dogs (7.4%)
Medicinal Odor	5 dogs (3.9%)	None observed
Lethargy	1 dog (0.8%)	1 dog (1.5%)
Inappetence	1 dog (0.8%)	1 dog (1.5%)
Hyperactivity	1 dog (0.8%)	None observed

During a field study using 61 dogs with pre-existing flea allergy dermatitis, one (1.6 %) dog experienced localized pruritus immediately after imidacloprid application, and one investigator noted hyperkeratosis at the application site of one dog (1.6 %).

In a field safety and effectiveness study, *Advantage Multi for Dogs* was administered to 92 client-owned dogs with sarcoptic mange. The dogs ranged in age from 2 months to 12.5 years and ranged in weight from 3 to 231.5 pounds. Adverse reactions in dogs treated with *Advantage Multi for Dogs* included hematochezia, diarrhea, vomiting, lethargy, inappetence, and pyoderma.

Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced weakness, depression, and unsteadiness between 6 and 9 days after application with *Advantage Multi for Dogs*. The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after application of *Advantage Multi for Dogs*.

The following clinical observations also occurred in laboratory effectiveness studies following application with *Advantage Multi for Dogs* and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vomiting, anorexia, lethargy, coughing, ocular discharge and nasal discharge. Observations at the application sites included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 hours.

Heartworm-Positive Dogs

Field Study: A 56-day field safety study was conducted in 214 *D. immitis* heartworm and microfilaria positive dogs with Class 1, 2 or 3 heartworm disease. All dogs received *Advantage Multi for Dogs* on Study Days 0 and 28; 108 dogs also received melarsomine dihydrochloride on Study Days – 14, 14, and 15. All dogs were hospitalized for a minimum of 12 hours following each treatment. Effectiveness against circulating *D. immitis* microfilariae was > 90 % at five of six sites; however, one site had an effectiveness of 73.3 %. The microfilaria count in some heartworm-positive dogs increased or remained unchanged following treatment with *Advantage Multi for Dogs* alone or in a dosing regimen with melarsomine dihydrochloride.

Following treatment with *Advantage Multi for Dogs* alone or in a dosing regimen with melarsomine dihydrochloride, the following adverse reactions were observed:

Adverse Reaction	Dogs Treated with Advantage Multi for Dogs Only n = 106	Dogs Treated with Advantage Multi for Dogs + Melarsomine n = 108
Cough	24 (22.6%)	25 (23.1%)
Lethargy	14 (13.2%)	42 (38.9%)
Vomiting	11 (10.4%)	18 (16.7%)
Diarrhea, including hemorrhagic	10 (9.4%)	22 (20.4%)
Inappetence	7 (6.6%)	19 (17.6%)
Dyspnea	6 (5.7%)	10 (9.3%)
Tachypnea	1 (< 1%)	7 (6.5%)
Pulmonary Hemorrhage	0	1 (< 1%)
Death	0	3 (2.8%)

Three dogs treated with *Advantage Multi for Dogs* in a dosing regimen with melarsomine dihydrochloride died of pulmonary embolism from dead and dying heartworms. One dog, treated with *Advantage Multi for Dogs* and melarsomine dihydrochloride, experienced pulmonary hemorrhage and responded to supportive medical treatment. Following the first treatment with *Advantage Multi for Dogs* alone, two dogs experienced adverse reactions (coughing, vomiting, and dyspnea) that required hospitalization. In both groups, there were more adverse reactions to *Advantage Multi for Dogs* following the first treatment than the second treatment.

To report a suspected adverse reaction, call 888-545-5973.

Post-Approval Experience (2022)

The following adverse events are based on post-approval adverse drug experience reporting for *Advantage Multi for Dogs*. Not all adverse events are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data.

The following adverse events reported in dogs are listed in decreasing order of reporting frequency: depression/lethargy, pruritus, vomiting, diarrhea, anorexia, application site reactions (alopecia, pruritus, erythema, and lesions, including blisters), hyperactivity, ataxia, trembling, seizures, panting, hypersalivation, anaphylaxis/anaphylactic reactions (hives, facial swelling, edema of the head), and corneal ulceration.

Serious reactions, including neurologic signs and death have been reported when cats have been exposed (orally and topically) to this product.

In humans, nausea, numbness or tingling of the mouth/lips and throat, ocular and dermal irritation, pruritus, headache, vomiting, diarrhea, depression and dyspnea have been reported following exposure to this product.

Contact Information:

For product questions, to report adverse drug experiences, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

ANIMAL SAFETY:

Heartworm-Negative Dogs

Field Study: In a controlled, double-masked, field safety study, *Advantage Multi for Dogs* was administered to 128 dogs of various breeds, 3 months to 15 years of age, weighing 4 to 157 pounds. *Advantage Multi for Dogs* was used safely in dogs concomitantly receiving ACE inhibitors, anticonvulsants, antihistamines, antimicrobials, chondroprotectants, corticosteroids, immunotherapeutics, MAO inhibitors, NSAIDs, ophthalmic medications, sympathomimetics, synthetic estrogens, thyroid hormones, and urinary acidifiers. Owners reported the following signs in their dogs after application of *Advantage Multi for Dogs:* pruritus, flaky/greasy residue at the treatment site, medicinal odor, lethargy, inappetence, and hyperactivity.
(See ADVERSE REACTIONS.)

Safety Study in Puppies: *Advantage Multi for Dogs* was applied topically at 1, 3 and 5X the recommended dose to 7-week-old Beagle puppies once every 2 weeks for 6 treatments on days 0, 14, 28, 42, 56, and 70. Loose stools and diarrhea were observed in all groups, including the controls, throughout the study. Vomiting was seen in one puppy from the 1X treatment group (day 57), in two puppies from the 3X treatment group (days 1 and 79), and in one puppy from the 5X treatment group (day 1). Two puppies each in the 1X, 3X, and 5X groups had decreased appetites within 24 hours post-dosing. One puppy in the 1X treatment group had pruritus for one hour following the fifth treatment. A puppy from the 5X treatment group displayed rapid, difficult breathing from 4 to 8 hours following the second treatment.

Dermal Dose Tolerance Study: *Advantage Multi for Dogs* was administered topically to 8-month-old Beagle dogs at 10X the recommended dose once. One dog showed signs of treatment site irritation after application. Two dogs vomited, one at 6 hours and one at 6 days post-treatment. Increased RBC, hemoglobin, activated partial thromboplastin, and direct bilirubin were observed in the treated group. Dogs in the treated group did not gain as much weight as the control group.

Oral Safety Study in Beagles: *Advantage Multi for Dogs* was administered once orally at the recommended topical dose to 12 dogs. Six dogs vomited within 1 hour of receiving the test article, 2 of these dogs vomited again at 2 hours, and 1 dog vomited again up to 18 hours post-dosing. One dog exhibited shaking (nervousness) 1 hour post-dosing. Another dog exhibited abnormal neurological signs (circling, ataxia, generalized muscle tremors, and dilated pupils with a slow pupillary light response) starting at 4 hours post-dosing through 18 hours post-dosing. Without treatment, this dog was neurologically normal at 24 hours and had a normal appetite by 48 hours post-dosing.
(See CONTRAINDICATIONS.)

Dermal Safety Study in Ivermectin-Sensitive Collies: *Advantage Multi for Dogs* was administered topically at 3 and 5X the recommended dose every 28 days for 3 treatments to Collies which had been prescreened for avermectin sensitivity. No clinical abnormalities were observed.

Oral Safety Study in Ivermectin-Sensitive Collies: *Advantage Multi for Dogs* was administered orally to 5 pre-screened ivermectin-sensitive Collies. The Collies were asymptomatic after ingesting 10 % of the minimum labeled dose. At 40 % of the minimum recommended topical dose, 4 of the dogs experienced neurological signs indicative of avermectin toxicity including depression, ataxia, mydriasis, salivation, muscle fasciculation, and coma, and were euthanized.
(See CONTRAINDICATIONS.)

Heartworm-Positive Dogs

Laboratory Safety Study in Heartworm-Positive Dogs: *Advantage Multi for Dogs* was administered topically at 1 and 5X the recommended dose every 14 days for 3 treatments to dogs with adult heartworm infections and circulating microfilaria. At 5X, one dog was observed vomiting three hours after the second treatment. Hypersensitivity reactions were not seen in the 5X treatment group. Microfilaria counts decreased with treatment.

STORAGE INFORMATION:

Store at temperatures between 4 °C (39 °F) and 25 °C (77 °F), avoiding excess heat or cold.

HOW SUPPLIED:

Applications Per Package
6 x 0.4 mL tubes
6 x 1.0 mL tubes
6 x 2.5 mL tubes
6 x 4.0 mL tubes
6 x 5.0 mL tubes

Revised: January 2023

Approved by FDA under NADA # 141-251

Made in Germany

Manufactured for:
Elanco US Inc
Greenfield, IN 46140 U.S.A.

Bexacat™ (bexagliflozin tablets)

15 mg flavored tablets
For oral use in cats only
Sodium-glucose cotransporter 2 (SGLT2) inhibitor

CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

WARNING: DIABETIC KETOACIDOSIS/EUGLYCEMIC DIABETIC KETOACIDOSIS
- **Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis (see Adverse Reactions). As diabetic ketoacidosis and euglycemic diabetic ketoacidosis in cats treated with Bexacat may result in death, development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat (see Monitoring).**
- **Due to the risk of developing diabetic ketoacidosis or euglycemic diabetic ketoacidosis, do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus (see Contraindications).**
- **Bexacat should not be initiated in cats with anorexia, dehydration or lethargy at the time of diagnosis of diabetes mellitus or without appropriate screening tests (see Animal Safety Warnings).**

DESCRIPTION
Bexacat (bexagliflozin tablets) are flavored pentagonal, 10 mm, speckled white, brown, or tan biconvex with a characteristic odor. The empirical formula is $C_{24}H_{29}ClO_7$ and the molecular weight is 464.94 g/mol. The chemical name is (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
The chemical structure of bexagliflozin is:



INDICATION
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

DOSAGE AND ADMINISTRATION
Always provide the Client Information Sheet with the prescription.

Dosing Instructions
Administer one tablet by mouth to cats weighing 6.6 lbs (3.0 kg) or greater once daily, at approximately the same time each day, with or without food, and regardless of blood glucose level.

Monitoring
- Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level.
- During treatment with Bexacat, blood glucose, fructosamine, serum β-hydroxybutyrate (BHBA), serum feline pancreas-specific lipase (fPL), liver parameters, serum cholesterol and triglycerides; and body weight and clinical signs should be routinely monitored.
  - Increasing or persistently elevated feline pancreas-specific lipase or liver parameters should prompt further evaluation for pancreatitis and/or hepatic disease and consideration for discontinuing Bexacat.
  - BHBA is the predominate ketoacid in diabetic ketoacidosis. Bexacat should be discontinued if a notable reduction in BHBA is not observed after initiation of Bexacat, or if BHBA persistently rises after an initial reduction.
  - Cats with increasing or persistently elevated cholesterol and triglyceride levels may be at an increased risk for developing diabetic ketoacidosis or euglycemic diabetic ketoacidosis.
  - Bexacat should be discontinued if poor glycemic control, as described below, develops.
- During the first 8 weeks after initiation of Bexacat, assessment of glycemic control and clinical improvement should be evaluated.
  - A physical examination, an 8-hour blood glucose curve, serum fructosamine and body weight should be assessed at 2, 4 and 8 weeks.
  - Cats demonstrating poor glycemic control, including weight loss, an average blood glucose concentration from an 8-hour blood glucose curve ≥ 250 mg/dL, and/or a fructosamine indicating poor glycemic control should be closely monitored.
  - Bexacat should be discontinued, and initiation of insulin considered in cats demonstrating poor glycemic control, as described above, at 8 weeks.
- Cats may present with diabetic ketoacidosis and a normal blood glucose concentration (euglycemic diabetic ketoacidosis). Delay in recognition and treatment of diabetic ketoacidosis and euglycemic diabetic ketoacidosis may result in increased morbidity and mortality.
- Development of diabetic ketoacidosis and euglycemic diabetic ketoacidosis requires the following actions:
  - Discontinuation of Bexacat
  - Prompt initiation of insulin therapy
  - Administration of dextrose or other carbohydrate source, regardless of blood glucose concentration
  - Appropriate nutritional support should be promptly initiated to prevent or treat hepatic lipidosis.

For more information refer to **CONTRAINDICATIONS** and **WARNINGS.**

CONTRAINDICATIONS
- Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.
- Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function.

WARNINGS
User Safety Warnings
Not for use in humans. Keep out of reach of children. Consult a physician in case of accidental ingestion by humans.

Animal Safety Warnings
- Bexacat should not be initiated in cats with:
  - Anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.
  - An fPL level > 5.3 mcg/L, diagnostic imaging consistent with pancreatitis, a history of pancreatitis, or current clinical signs suggestive of pancreatitis.
  - Laboratory values consistent with diabetic ketoacidosis, including elevated urine or serum ketones, and metabolic acidosis (high anion gap, or decreased bicarbonate, pH, or partial pressure carbon dioxide [PaCO2] levels).
  - A BHBA > 37 mg/dL, or if BHBA is > 25 mg/dL and the cat has a history of renal disease or metabolic acidosis.
- Persistent plasma bexagliflozin concentrations and reduced clearance of Bexacat, represented as the presence of plasma half-lives in excess of 24 hours, may result in prolonged clinical effects such as glucosuria and/or euglycemia despite discontinuation of Bexacat in some cats with hepatic disease and/or reduced renal function, including cats with clinically undetectable disease at the time of Bexacat initiation. Reduced clearance of Bexacat may contribute to persistent glucosuria, resulting in an osmotic diuresis and dehydration that requires appropriate hydration support. These cats may require hospitalization, which may be protracted, for sequalae such as diabetic ketoacidosis, euglycemic diabetic ketoacidosis, or hepatic lipidosis.
- Cats should be screened for urinary tract infections and treated, if indicated, when initiating Bexacat. Treatment with Bexacat may increase the risk for urinary tract infections (see **Adverse Reactions**). Cats treated with Bexacat should be monitored for urinary tract infections and treated promptly. Consider discontinuation of Bexacat in cats with recurrent urinary tract infections.
- Bexacat may cause increased serum calcium concentrations. Bexacat should be discontinued in cats with persistent increases in serum total calcium or ionized calcium because of increased risk of forming calcium containing uroliths (see **Adverse Reactions**).
- Long term use of Bexacat may increase the risk of urothelial carcinoma (see **Adverse Reactions**).
- Keep Bexacat in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

PRECAUTIONS
- Bexacat should be discontinued in cats who develop diarrhea unresponsive to conventional therapy.
- Consider temporary discontinuation of Bexacat in cats during times of decreased caloric intake, such as surgery or decreased appetite, as administration of Bexacat in these cats may increase the risk of diabetic ketoacidosis or hepatic lipidosis.
- The osmotic diuretic effects of Bexacat may contribute to inappropriate urination in some cats (see **Adverse Reactions**).
- Polyphagia as a compensatory response to caloric wasting from glucosuria may persist in up to 80% of cats, despite evidence of adequate glycemic control, and may lead to progressive weight gain.
- Approximately 20-30% of cats may have persistent polyuria and/or polydipsia secondary to Bexacat-induced osmotic diuresis and may be a risk factor for dehydration-associated diabetic ketoacidosis.
- The concurrent use of volume depleting drugs in cats treated with Bexacat has not been evaluated.
- The safety of Bexacat in breeding, pregnant, and lactating cats has not been evaluated.

ADVERSE REACTIONS
Field Study
Eighty-four cats with newly diagnosed diabetes mellitus were enrolled in a 180-day multicenter field effectiveness and safety study. Safety data were evaluated in 84 cats treated with at least one dose of Bexacat. All cats received one tablet, once daily, regardless of body weight or blood glucose level. Seventy-two of the 84 enrolled cats completed the study. The most common adverse reactions included elevated blood urea nitrogen (BUN), vomiting, elevated urine specific gravity (USG), elevated serum fPL, diarrhea, anorexia, lethargy, and dehydration. The adverse reactions seen during the field study are summarized in Table 1 below.

Table 1. Adverse Reactions (n=84)

Adverse Reaction	Number (%)
Elevated BUN*	46 (54.8)
Vomiting	42 (50.0)
Elevated USG†	33 (39.3)
Elevated fPL‡	33 (39.3)
Diarrhea	32 (38.1)
Anorexia	31 (37.0)
Lethargy	17 (20.2)
Dehydration	16 (19.0)
Elevated symmetrical dimethylarginine (SDMA)	13 (15.5)
Weight loss	13 (15.5)
Urinary tract infection	12 (14.3)

Adverse Reaction	Number (%)
Elevated ALT and/or AST§	11 (13.1)
Hypercalcemia	8 (9.5)
Behavioral changes**	6 (7.1)
Proteinuria	5 (6.0)
Elevated creatinine	4 (4.8)
Elevated creatine kinase	4 (4.8)
Inappropriate urination	4 (4.8)
Death	3 (3.6)
Diabetic ketoacidosis	3 (3.6)
Pancreatitis	3 (3.6)
Euglycemic diabetic ketoacidosis	2 (2.4)
Hepatic lipidosis	2 (2.4)
Elevated alkaline phosphatase	2 (2.4)
Elevated total bilirubin	2 (2.4)
Constipation	2 (2.4)

* Most cats had elevations < 1.5 times the upper limit of normal (ULN).
† Elevations were predominantly attributable to dehydration and/or glucosuria.
‡ Most cats had one or more isolated elevations, followed by a return to previous values.
§ Of nine cats with elevations ≥ 1.5X ULN, 2 cats developed diabetic ketoacidosis and were transitioned to insulin. One cat developed diabetic ketoacidosis and hepatic lipidosis resulting in death (euthanasia). One cat developed anemia, progressive weight loss and fPL elevations resulting in death.
** Observations included hiding, agitation, aggression, vocalization, and anxious behavior.

Nine serious adverse reactions associated with Bexacat administration occurred during the study, including three cats who died or were euthanized. Of the three cats who died or were euthanized, two cats became clinically ill within 5 doses of Bexacat administration (range 3 to 5 doses). One cat with euglycemic diabetic ketoacidosis and hepatic lipidosis was euthanized due to further deterioration of its clinical condition, despite supportive treatment. One cat demonstrating anorexia, lethargy, dehydration, azotemia, and hypokalemia was euthanized without supportive treatment. One cat, who demonstrated a lack of effectiveness, anemia and hepatic lipidosis died on Day 77 despite supportive treatment and additional diagnostics. Six of the nine cats had serious adverse reactions that did not result in death or euthanasia. Five cats were treated for their clinical conditions and transitioned to insulin. Serious adverse reactions in these cats were associated with the following conditions (number of cats): euglycemic diabetic ketoacidosis (1); lack of effectiveness, diabetic ketoacidosis, elevated liver parameters (1); diabetic ketoacidosis (1); diabetic ketoacidosis and pyelonephritis (1); and lack of effectiveness, weight loss, dehydration (1). One cat with constipation and pancreatitis received supportive treatment and remained on Bexacat (bexagliflozin tablets).

Pilot Field Study

Eighty-nine cats with newly diagnosed diabetes mellitus were enrolled in a 56-day multicenter pilot field effectiveness and safety study, with continued use for up to 180 days. All cats received one tablet, once daily, regardless of body weight or blood glucose level. Safety data were evaluated for all 89 cats treated with at least one dose of bexagliflozin. The most common adverse reactions included elevated blood urea nitrogen (BUN), elevated urine specific gravity (USG), elevated serum feline pancreas-specific lipase, vomiting, diarrhea/loose stool, hyporexia/anorexia, lethargy, elevated serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and urinary tract infections. The adverse reactions seen in the pilot study are summarized in Table 2 below.

Table 2. Adverse Reactions (n=89)

Adverse Reaction	Number (%)
Elevated BUN*	51 (57.3)
Elevated USG†	43 (48.3)
Elevated fPL‡	39 (43.8)
Vomiting	39 (43.8)
Diarrhea/Loose Stool	29 (32.6)
Hyporexia/Anorexia	28 (31.4)
Lethargy	16 (18.0)
Elevated ALT and/or AST§	13 (14.6)
Urinary tract infection	13 (14.6)
Dehydration	10 (11.2)
Elevated symmetrical dimethylarginine (SDMA)	10 (11.2)
Behavioral changes**	9 (10.1)
Ketosis/Ketonuria	8 (9.0)
Weight loss	8 (9.0)
Proteinuria	8 (9.0)
Pancreatitis	7 (7.9)
Death	6 (6.7)
Anemia	6 (6.7)
Hepatopathy	6 (6.7)
Hypercalcemia	4 (4.5)
Elevated creatine kinase	4 (4.5)
Inappropriate urination	4 (4.5)
Peritonitis	3 (3.4)
Constipation	3 (3.4)
Elevated creatinine	2 (2.2)
Euglycemic diabetic ketoacidosis	2 (2.2)
Diabetic ketoacidosis	2 (2.2)
Hemolytic anemia	2 (2.2)
Elevated total bilirubin	2 (2.2)

* Most cats had elevations ≤ 1.5X upper limit of normal (ULN).
† Elevations were predominantly attributable to dehydration and/or glucosuria.
‡ Most cats had one or more isolated elevations, followed by a return to previous values.
§ Most elevations were ≤ 2X ULN. One cat had marked ALT and AST (9X and 6X upper limit of normal, respectively) elevations on Day 28. Following discontinuation of bexagliflozin, the liver enzymes decreased within 24 hours and returned to within reference range in 10 days.
** Observations included hiding, hyperactivity, vocalization, and abnormal behavior.

Twenty cats (22%) had at least one blood glucose value < 65 mg/dL recorded during 8-hour blood glucose curves. No clinical signs of hypoglycemia were observed and bexagliflozin dosing was not adjusted in any cat due to documented hypoglycemia. Nine serious adverse reactions associated with bexagliflozin administration occurred during the study, including six cats who died or were euthanized. Of the six cats who died or were euthanized, five became clinically ill within receiving 5 doses of bexagliflozin (range 1 to 5 doses). Four of the cats were euthanized due to further deterioration of their clinical condition despite supportive treatment. One cat died despite supportive treatment. Deaths were associated with the following conditions (number of cats): necrotizing pancreatitis and pancreatic abscess (1), pancreatitis and hepatic lipidosis (1), euglycemic diabetic ketoacidosis and severe hepatic lipidosis (1), pancreatitis and hepatic abscesses (1), diabetic ketoacidosis (1), and persistent polyuria and polydipsia and quality of life concerns (1).

Three of nine serious adverse reactions that did not result in death or euthanasia included the following (number of cats): acute hepatocellular injury (1), immune-mediated hemolytic anemia (1), and euglycemic diabetic ketoacidosis with concurrent pancreatitis and hepatopathy (1). Two cats with serious adverse reactions demonstrated persistent bexagliflozin blood plasma levels and elimination half-lives after discontinuation of bexagliflozin. One cat with renal and liver values within the reference range at screening was euthanized due to a continued decline in clinical condition despite treatment for euglycemic diabetic ketoacidosis and severe hepatic lipidosis. The second cat, noted to have IRIS (International Renal Interest Society) stage II renal disease and liver values within the reference range at screening, recovered following treatment for marked liver enzyme elevations above the reference range on Day 28.

Extended Use Field Study

One hundred twenty-five cats with diabetes mellitus that had previously completed a bexagliflozin field study were enrolled in a multicenter extended use field study. Cats were enrolled in the study for a range of 7 to 1064 days, with a mean of 329 days. Safety data were evaluated for all 125 cats treated with at least one dose of Bexacat (bexagliflozin tablets). All cats received one tablet, once daily, regardless of body weight or blood glucose level. Forty-nine of the 125 enrolled cats were withdrawn from the study due to adverse reactions, serious adverse reactions, death/euthanasia, lack of effectiveness, suspected diabetic remission, withdrawal of owner consent, or lost to follow up. The most common adverse reactions were similar to those noted in the previous field studies and included elevated USG (35.2%), vomiting (27.2%), elevated fPL (26.4%), anorexia (24.0%), diarrhea (22.4%), urinary tract infections (17.6%), lethargy (16.8%), and death (16.0%).

Twenty serious adverse reactions associated with Bexacat administration occurred during the study, all resulting in death or euthanasia. Clinical signs of hypoglycemia were observed in two of these cats. Deaths were associated with the following conditions (number of cats), with some cats experiencing multiple comorbidities (necropsy was not granted in all cases): euglycemic diabetic ketoacidosis (8); diabetic ketoacidosis (4); hepatic lipidosis (5); pancreatic necrosis/peripancreatic fat saponification (3); urothelial carcinoma (2); hypercalcemia, recurrent calcium containing cystic calculi (1); lack of effectiveness, weight loss, anorexia (1); lethargy, weight loss, pallor (1); chronic renal disease, glomerulonephritis (1); chronic enteropathy (1); hypoglycemia, possible pancreatitis (1).

CONTACT INFORMATION

To report suspected adverse events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US Inc at 1-888-545-5973.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

INFORMATION FOR CAT OWNERS

Owners should be given the Client Information Sheet to read before Bexacat is administered. Owners should be advised to discontinue Bexacat and contact a veterinarian immediately if their cat develops anorexia, lethargy, vomiting, diarrhea, or weakness.

CLINICAL PHARMACOLOGY

Mechanism of Action

Bexagliflozin is an inhibitor of sodium-glucose cotransporter 2 (SGLT2), the renal transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion.

Pharmacokinetics

In a laboratory pilot study conducted to determine the prandial state of maximum exposure, systemic exposure for bexagliflozin was greater in the fasted state than in the fed state by 82% for the mean maximum observed plasma concentration (C_{max}), and by 54% for the mean area under the plasma concentration versus time curve (AUC) from dosing (time 0) to the last quantifiable concentration ($AUC_{0\text{-last}}$), respectively.

In a well-controlled margin of safety study (see **Target Animal Safety**), mean C_{max} was approximately dose-proportional over a dosage range of 5 mg/kg (1X) to 25 mg/kg (5X). Mean AUC from time 0 to 24 hours exposure was approximately dose-proportional over a dosage range of 5 to 15 mg/kg, but more than dose-proportional at 15 to 25 mg/kg. An increase in exposure ($AUC_{0\text{-}24}$ and C_{max}), was observed in female cats compared to male cats on all evaluation days. Median time to reach peak plasma concentration (T_{max}) was approximately 0.5 hours (range 0.5 to 2 hours) and mean half-life ($T_{1/2}$) was approximately 5 hours across all dose groups. There was no accumulation of bexagliflozin following daily dosing of 5, 15, and 25 mg/kg in healthy non-diabetic cats. However, field studies showed that some diabetic cats had persistent bexagliflozin blood levels after discontinuation of the drug, which may be related to a decrease in liver function in some cats (see **Animal Safety Warnings**).

EFFECTIVENESS

Field Study

Eighty-four cats diagnosed with diabetes mellitus were enrolled in a 180-day multicenter field effectiveness and safety study. Enrolled cats included purebreds and mixed breeds, ranging in age from 3 to 19 years, and weighing between 7.3 to 24.3 lbs (3.3 to 11.3 kg). Cats received one tablet, once daily, regardless of body weight or blood glucose level. Treatment success was defined as improvement in at least one blood glucose variable (blood glucose curve mean or fructosamine) and improvement in at least one clinical sign of diabetes mellitus (polyuria, polydipsia, polyphagia, or body weight [weight gain or no weight loss]).

Of 77 cats included in the effectiveness-evaluable population:

- 64 cats (83.1%) were considered a treatment success on Day 56.
- The lower bound two-sided 90% confidence interval was 74.5%. Effectiveness was demonstrated if the lower bound of the confidence interval was > 66%.
- Mean blood glucose curve mean decreased from 284 mg/dL on Day 0 to 143 mg/dL on Day 56.
- Mean fructosamine levels decreased from 544 µmol/L prior to Day 0 to 295 µmol/L on Day 56.
- Improvements in the clinical signs of polyuria, polydipsia, polyphagia, and body weight on Day 56 were observed in 53 (68.8%), 57 (74.0%), 44 (57.1%), and 42 (54.6%) cats, respectively.
- 66 cats (85.7%) completed the 180-day study.

Pilot Field Study

Eighty-nine cats diagnosed with diabetes mellitus were enrolled in a 56-day, multicenter pilot field effectiveness and safety study with continued use for up to 180 days. Enrolled cats included purebreds and mixed breeds, ranging in age from 3 to 17 years and weighing 6.4 to 22.9 lbs (2.9 to 10.4 kg). Cats received one tablet, once daily, regardless of weight. Treatment success was defined as improvement in at least one blood glucose variable (blood glucose curve mean or fructosamine) and improvement in at least one clinical sign of diabetes mellitus (polyuria, polydipsia, polyphagia, or body weight [weight gain or no weight loss]). Of the 72 cats included in the effectiveness-evaluable population, 58 (80.6%) were considered treatment successes on Day 56.

TARGET ANIMAL SAFETY

In a well-controlled laboratory margin of safety study, Bexacat was administered orally to 28 fasted, healthy, lean, intact adult cats at doses of at least 1X (8 cats), 3X (8 cats), and 5X (12 cats) the maximum exposure dose (5 mg/kg) once daily for 26 weeks. The control group (8 cats) was sham dosed. The maximum exposure dose (5 mg/kg) was based on the assessment that the minimum weight of an eligible cat with diabetes mellitus is approximately 3 kg. Polyuria, glucosuria (with a corresponding increase in food consumption), loose stools and diarrhea, and ketonuria were reported more frequently in cats that received Bexacat than in control cats. There were drug-related clinically insignificant increases in calcium, magnesium, and cholesterol levels, and decreases in creatinine and amylase levels, and blood pressure and heart rate values. Gross necropsy demonstrated treatment-related observations of mild, diffuse zonal patterns in the liver. One cat with the observed zonal pattern had mild elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and a histopathological observation of minimal, multifocal necrosis in the liver. The histopathological finding did not correspond to the zonal patterns observed grossly. There were no clinically relevant, drug-related effects on hematology and coagulation parameters and organ weight values.

STORAGE CONDITIONS Bexacat should be stored at room temperature 68 to 77 °F (20 to 25 °C).

HOW SUPPLIED

Flavored tablet each containing 15 mg bexagliflozin; 30 or 90 tablets per bottle.

Approved by FDA under NADA # 141-566
Manufactured for: Elanco US Inc, Greenfield, IN 46140

September 2022

For use in cats only

Zorbium™ C-III

(buprenorphine transdermal solution)

20 mg/mL

For topical application in cats
Opioid analgesic

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

HUMAN SAFETY WARNING

Abuse Potential

ZORBIUM contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ZORBIUM. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drugs or alcohol) or mental illness (e.g. depression).

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM. Monitor for respiratory depression if human exposure to buprenorphine occurs. Misuse or abuse of buprenorphine by swallowing, snorting, or injecting poses a significant risk of overdose and death.

Accidental Exposure

Because of the potential for adverse reactions associated with accidental exposure, ZORBIUM should only be administered by veterinarians or veterinary technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM, especially in children, can result in a fatal overdose of buprenorphine.

Risks From Concurrent Misuse or Abuse with Benzodiazepines or Other CNS Depressants

Concurrent misuse or abuse of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

See Human Safety Warnings for detailed information.

DESCRIPTION:

ZORBIUM is a volatile liquid transdermal solution intended for topical application that provides continuous, systemic delivery of the opioid analgesic, buprenorphine. Buprenorphine belongs to the opioid class of drugs and is a narcotic under the Controlled Substances Act due to its chemical derivation from thebaine. Once ZORBIUM is applied to the skin, rapid drying results in dermal absorption and sequestration of buprenorphine into the stratum corneum. Each mL of ZORBIUM contains 20 mg buprenorphine (administered as 21.56 mg of buprenorphine hydrochloride). The inactive ingredients are dehydrated alcohol, padimate O, butylated hydroxyanisole, and butylated hydroxytoluene.

Buprenorphine hydrochloride has an empirical formula of $C_{29}H_{41}NO_4$•HCl and a molecular weight of 504.10. The chemical structure of buprenorphine HCl is:



INDICATION:

ZORBIUM is indicated for the control of postoperative pain associated with surgical procedures in cats.

DOSAGE AND ADMINISTRATION:

This product should only be administered by veterinary personnel.

ZORBIUM is for administration only once for the surgical procedure. ZORBIUM should be applied 1 to 2 hours before surgery. A single application provides analgesia for 4 days. ZORBIUM should only be applied topically to the dorsal cervical area at the base of the skull. Do not apply if dorsal cervical skin is diseased or injured. The dosage of ZORBIUM is 1.2 – 3.1 mg/lb (2.7 – 6.7 mg/kg) administered topically as the entire tube contents according to the following dosing table:

Pounds of Body Weight	Kilograms of Body Weight	Dose of ZORBIUM
2.6 to 6.6	1.2 to 3	0.4 mL (8 mg) pink tube
>6.6 to 16.5	>3 to 7.5	1 mL (20 mg) green tube

Dose Application

Wear impermeable latex or nitrile gloves, protective glasses, and a laboratory coat to prevent direct solution contact with human skin, eyes, or mucosa when handling and applying the solution. Do not dispense ZORBIUM for administration at home by the pet owner (see HUMAN SAFETY WARNINGS).

Figure 1 - Diagram of tube components.



Rotate applicator tip to open.
Applicator tip is not removable.

Figure 2 – Proper grasp of the applicator tube: To prepare to open the tube for application, the tube must be held in an upright position to avoid spilling contents. Grasp the tube just beneath the ribbed portion of the tip.

Figure 3 – Opening the applicator tube: Keeping the tube upright, grasp the ribbed portion of the tip, and turn the applicator tip in either direction at least 180° to open the tube. **The applicator tip is designed to stay on the tube and should not be removed.** The tube is ready for application when a breaking of the seal is felt.



Figure 4 – Solution application: Fur should not be clipped. Do not apply to injured or diseased skin. Gently hold the cat both before and after application to prevent the cat from shaking or rubbing. Part the fur and apply the tip of the tube directly onto the skin at the base of the head. Squeeze the tube 2 – 3 times to empty the contents without moving the tube or the tip. Lift the tube directly away from the skin, avoiding contact of the tip with the cat's fur.



CONTRAINDICATIONS:

ZORBIUM is contraindicated in cats with known hypersensitivity to buprenorphine hydrochloride, any of the inactive ingredients of ZORBIUM, or known intolerance to opioids.

WARNINGS:

HUMAN SAFETY WARNINGS:

Not for use in humans. Keep this and all medications out of reach of children and pets.

Human User Safety While Handling ZORBIUM in the Hospital:

Protective Covering: Do not come into direct contact with ZORBIUM. Wear impermeable latex or nitrile gloves, protective glasses, and a laboratory coat when applying ZORBIUM.

Mucous Membrane or Eye Contact During Application:

Direct contact of ZORBIUM with the eyes, oral, or other mucous membranes could result in absorption of buprenorphine and the potential for adverse reactions. If accidental eye, oral, or other mucous membrane contact is made during application, flush the area with water and contact a physician immediately. If wearing contact lenses, flush the eye first and then remove the contact lens.

Skin Contact During Application:

Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. If human skin is accidentally exposed to ZORBIUM, wash the exposed area immediately with soap and water and contact a physician. Accidental exposure could result in absorption of buprenorphine and the potential for adverse reactions.

Drug Abuse, Addiction, and Diversion of Opioids:

Controlled Substance:

ZORBIUM contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids.

Abuse:

ZORBIUM contains buprenorphine, an opioid substance, that can be abused and is subject to misuse, abuse, and addiction, which may lead to overdose and death. This risk is increased with concurrent use of alcohol and other central nervous system depressants, including other opioids and benzodiazepines.

ZORBIUM should be handled appropriately to minimize the risk of diversion, including restriction of access, the use of accounting procedures, and proper disposal methods, as appropriate to the clinical setting and as required by law.

Prescription drug abuse is the intentional, non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. Buprenorphine has been diverted for non-medical use into illicit channels of distribution. All people handling opioids require careful monitoring for signs of abuse.

Storage and Disposal:

ZORBIUM is a Schedule III opioid. Store in a locked cabinet according to federal and state controlled substance requirements/guidelines. Any unused or expired tubes must be destroyed by a reverse distributor; for further information, contact your local DEA field office or call Elanco US Inc. at 1-888-545-5973.

Information for Physician:

ZORBIUM transdermal solution contains a mu opioid partial agonist (20 mg buprenorphine/mL). In the case of an emergency, provide the physician with this package insert. Naloxone may not be effective in reversing respiratory depression produced by buprenorphine. The onset of naloxone effect may be delayed by 30 minutes or more. Doxapram hydrochloride has also been used as a respiratory stimulant.

ANIMAL SAFETY WARNINGS:

For topical use in cats only. **This product should only be administered by veterinary personnel.**

Do not apply ZORBIUM if the application site at the dorsal cervical area has diseased or injured skin.

Do not apply ZORBIUM to anatomic areas other than the dorsal cervical area because absorption characteristics may be different.

PRECAUTIONS:

Following anesthesia and opioid analgesia, body temperature should be monitored postoperatively for immediate hypothermia and subsequent hyperthermia. Hyperthermia can occur and persist after the hypothermic effects of anesthesia have resolved.

The safe use of ZORBIUM has not been evaluated in debilitated cats or cats with renal, hepatic, cardiac, or respiratory disease.

The safe use of ZORBIUM has not been evaluated in cats that are pregnant, lactating, or intended for breeding.

The safe use of ZORBIUM has not been evaluated in cats younger than four months old.

The safe use of ZORBIUM has not been evaluated in cats weighing less than 2.6 pounds or more than 16.5 pounds.

ADVERSE REACTIONS:

In a randomized, multi-centered, double-masked, field study, ZORBIUM™ (buprenorphine transdermal solution) (N=113) or vehicle control (N=109) was administered to cats prior to elective surgical reproductive sterilization (castration/ovariohysterectomy) in conjunction with forelimb onychectomy. Cats enrolled in the study were 4 months to 5 years of age and weighed 1.1 to 5.7 kg (2.5 to 12.5 lb). Clinical observations and physiological parameters were monitored prior to, during, and after surgery for 96 hours after sternal recumbency. Supplemental heat and fluids were allowed. There were no deaths during the study and no cats received an opioid reversal agent. Three ZORBIUM and 2 vehicle control cats were removed due to hyperthermia suspected to be treatment related. One ZORBIUM cat was removed due to fractious behavior 30 minutes following surgery. Adverse reactions were defined as any single excursion outside the normal range, as defined: 100.5 – 102.5 °F body temperature; 60 – 120 mmHg mean arterial pressure; 88 – 180 beats per minute for heart rate; 24 – 44 breaths per minute for respiratory rate. A summary of adverse reactions during anesthesia (from anesthetic induction through recovery defined as sternal recumbency) is provided in Table 1.

Table 1. Adverse Reactions During Anesthesia:

Adverse Reaction*	ZORBIUM (N=113)	Vehicle Control (N=109)
Hypothermia	37 (32.7%)	29 (26.6%)
Hypotension	31 (27.4%)	28 (25.7%)
Hypertension	27 (23.9%)	18 (16.5%)
Tachycardia	14 (12.4%)	14 (12.8%)
Sedation	12 (10.6%)	7 (6.4%)
Oxygen saturation ≤ 90%	6 (5.3%)	2 (1.8%)
Bradycardia	4 (3.5%)	2 (1.8%)
Hyperthermia	3 (2.7%)	4 (3.7%)

*Physiological adverse reactions were defined as any single excursion outside the normal range at any 10 minute interval during the entire duration of anesthesia.

After recovery, cats were observed in the hospital and underwent physiological assessments that included indirect mean arterial blood pressure, heart rate, respiratory rate, body temperature, lung auscultation, heart auscultation, and assessments of urination, defecation, and appetite. A summary of adverse reactions after anesthetic recovery (sternal recumbency) in all cats is reported in Table 2.

Table 2. Adverse Reactions After Anesthetic Recovery:

Adverse Reaction*	ZORBIUM (N=113)	Vehicle Control (N=109)
Hypothermia	107 (94.7%)	105 (96.3%)
Hyperthermia	84 (74.3%)	62 (56.9%)
Sedation	64 (56.6%)	48 (44.0%)
Tachypnea	56 (49.6%)	70 (64.2%)
Hypotension	50 (44.2%)	51 (46.8%)
Hypertension	42 (37.2%)	34 (31.2%)
Bradycardia	34 (30.1%)	45 (41.3%)
Tachycardia	32 (28.3%)	39 (35.8%)
Anorexia	25 (22.1%)	32 (29.4%)
Dysphoria	20 (17.7%)	29 (26.6%)
Diarrhea	11 (9.7%)	11 (10.1%)
Bradypnea	11 (9.7%)	7 (6.4%)
Leukocytosis	6 (5.3%)	4 (3.7%)
Hyperactivity	2 (1.8%)	9 (8.3%)

*Physiological adverse reactions were defined as any single excursion outside the normal range following anesthetic recovery (sternal recumbency) through 4 days postoperatively.

Hyperthermia was the only adverse event observed in more than 10% of cats in the ZORBIUM group after the day of surgery (24 – 96 hours). The percentage of cats in the ZORBIUM group with hyperthermia decreased over time from 66.4% on Day 0 to 28.3% on Day 1, and to 6.2% by Day 4. A summary of adverse reactions (from anesthetic recovery through 96 hours after recovery) in cats in the ZORBIUM group by study day is reported in Table 3.

Table 3. Adverse Reactions in ZORBIUM Cats (N=113) by Day:

Adverse Reaction*	Day 0	Day 1	Day 2	Day 3	Day 4
Hypothermia	106 (93.8%)	2 (1.8%)	2 (1.8%)	2 (1.8%)	2 (1.8%)
Hyperthermia	75 (66.4%)	32 (28.3%)	18 (15.9%)	14 (12.4%)	7 (6.2%)
Sedation	64 (56.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Tachypnea	51 (45.1%)	5 (4.4%)	2 (1.8%)	3 (2.7%)	4 (3.5%)
Hypotension	42 (37.2%)	2 (1.8%)	1 (0.9%)	4 (3.5%)	2 (1.8%)
Hypertension	28 (24.8%)	2 (1.8%)	1 (0.9%)	1 (0.9%)	1 (0.9%)
Anorexia	25 (22.1%)	3 (2.7%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
Bradycardia	24 (21.2%)	3 (2.7%)	2 (1.8%)	3 (2.7%)	5 (4.4%)
Tachycardia	24 (21.2%)	4 (3.5%)	0 (0.0%)	1 (0.9%)	1 (0.9%)
Dysphoria	20 (17.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Bradypnea	8 (7.1%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Hyperactivity	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)

*Physiological adverse reactions were defined as any single excursion outside the normal range following anesthetic recovery (sternal recumbency) through 96 hours postoperatively.

CONTACT INFORMATION:

To report suspected adverse events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US Inc. at 1-888-545-5973.

For additional information about reporting adverse drug experience for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

CLINICAL PHARMACOLOGY:

Mechanism of Action: Buprenorphine exerts its analgesic effect via high affinity binding to various subclasses of opiate receptors, particularly mu, in the central nervous system. Buprenorphine analgesic and adverse reactions are mediated by mu opioid receptor agonism. Due to its partial agonist activity, buprenorphine exhibits a ceiling effect to its actions and thus has a greater therapeutic index compared to full mu opioid receptor agonists such as morphine. Buprenorphine binds tightly to and disassociates slowly from the opioid receptor. Therefore, the pharmacological effects of buprenorphine are not directly related to plasma concentrations.

Pharmacokinetics: Following application of ZORBIUM, solvent evaporation coupled with the permeation enhancer action results in rapid absorption and sequestration of the buprenorphine into the skin. ZORBIUM provides analgesia within 1 – 2 hours following administration and continually releases buprenorphine from the skin into the systemic circulation over a period of days. The mean (range) time to reach peak concentration (t_{max}) was 7.33 (1 – 24) hours. Due to buprenorphine elimination being faster than absorption from the skin, ZORBIUM exhibits flip-flop pharmacokinetics where the absorption determines its terminal half-life (mean 64.9 hours [range 39.1 – 85.7 hours]). The estimated absolute bioavailability (F) of transdermal administration was in the order of 16% [90% confidence interval (CI) =11.8% – 21.7%].

Buprenorphine is extensively metabolized by the liver in humans, the primary route being N-dealkylation to norbuprenorphine by cytochrome P450 enzymes. Both buprenorphine and norbuprenorphine form inactive glucuronide conjugates and are excreted by the bile into the gastrointestinal tract. The cat is devoid of uridine diphosphate glucuronosyltransferase enzymes (UGT1A6 and UGT1A9) responsible for conjugation and therefore conjugated metabolites may be absent. Norbuprenorphine is considered an active metabolite of buprenorphine, though it has one-fiftieth the analgesic activity of buprenorphine in rats. Buprenorphine extensively binds (95 – 98%) to plasma proteins.

EFFECTIVENESS:

The effectiveness of ZORBIUM was demonstrated in cats that underwent elective reproductive sterilization in conjunction with forelimb onychectomy surgery in a randomized, multi-centered, double-masked, vehicle-controlled, field study across 12 investigative sites. Enrolled cats were between 4 months to 5 years of age and weighed 2.5 to 12.5 pounds (1.1 – 5.7 kg).

Cats in the ZORBIUM group received a single dose of 8 mg or 20 mg of buprenorphine according to body weight (see DOSAGE AND ADMINISTRATION). Cats in the vehicle control group received a

transdermal solution of 50 mg/mL padimate O in ethanol. The dose was administered topically onto the dorsal cervical skin 1 – 2 hours prior to anesthetic induction for surgery. For intraoperative analgesia, all cats in the study received a single intramuscular injection of an alpha$_2$-agonist 30 minutes prior to anesthetic induction, and a 4-point metacarpal ring block with lidocaine after induction. The adequacy of pain control was scored through 96 hours after surgery. If pain control was considered inadequate at any time following treatment, rescue analgesia was provided immediately. Treatment success was defined as a cat that did not require rescue analgesia, need opioid reversal, or experience an adverse event suspected to be related to treatment through the entire 96-hour post-recovery period. A cat was considered a treatment failure if it had inadequate pain control, required opioid reversal, or experienced an adverse event suspected to be related to treatment.

A total of 19 ZORBIUM and 63 vehicle control cats were removed from the study due to inadequate pain control. Most of these failures occurred on the day of surgery in both groups; however, there were 4 ZORBIUM group cats and 5 vehicle control cats removed due to inadequate pain control between 1 and 3 days after surgery.

Effectiveness was evaluated in 219 cats (112 in the ZORBIUM group and 107 cats in the vehicle control group), and field safety was evaluated in 222 cats (113 cats in the ZORBIUM group and 109 cats in the vehicle control group). Of the 112 cats in the ZORBIUM group, 89 were treatment successes; of the 107 vehicle control cats, 42 were treatment successes. Comparison of the ZORBIUM group and the vehicle control group demonstrated a statistically significant difference in the treatment success rates ($p = 0.0003$).

Hypothermia was common in both groups during surgery. The overall mean postoperative body temperature was higher in the ZORBIUM group than in the vehicle control group. Mean postoperative body temperatures in the ZORBIUM group were above the normal range at 4 and 8 hours postoperatively (mean±SD of 102.7°±1.2 °F and 102.6°±1.0 °F, respectively [normal range: 100.5 – 102.5 °F]). Mean indirect arterial blood pressure (MAP) was similar between the 2 treatment groups over time. Urination, defecation, appetite, and daily body weights after surgery were not affected by ZORBIUM administration. Fifteen cats in the ZORBIUM group had an increased fibrinogen at discharge, compared to 2 cats in the vehicle control group.

Fluid administration (intravenous and subcutaneous) and supplemental heat support after surgery were the most common concurrent treatments and were used similarly in both groups.

TARGET ANIMAL SAFETY:

Twelve Day Target Animal Safety Study: In a 12-day laboratory study, ZORBIUM was administered to 32 healthy four-month-old domestic cats (8 cats per group) at 0 mg/kg (vehicle control), 6.7 mg/kg (1X), 13.3 mg/kg (2X), and 20 mg/kg (3X) as a topical application to the dorsal cervical area every 4 days for a total of 3 doses. Dose-independent euphoria, mild dysphoria, and mydriasis were observed after ZORBIUM administration. Maximum scores (for euphoria, dysphoria, and mydriasis) in the ZORBIUM groups reached 3 (mildly dysphoric) between 1 – 2 hours after the first dose. On the other 2 dosing days (Days 4 and 8), maximum scores were 2 (euphoric). Euphoria in some cats persisted from 36 to 72 hours.

On dosing day 1, mydriasis was observed in approximately half the cats administered ZORBIUM by 24 hours after dosing (peaked in all ZORBIUM groups at 8 hours) and was not observed between 48 – 93 hours. After the day 8 dose (third dose), it was rarely observed (1 cat in 1X group; 2 cats in 3X at 48 hours; 1 cat in 2X at 72 hours).

Cats administered ZORBIUM had higher body temperatures compared to the vehicle control group throughout the study. Following the initial dose, the mean temperatures in cats administered ZORBIUM increased above normal and were up to 1.8 ºF greater than the vehicle control group. Increased body temperature primarily occurred during the first 8 hours after the initial dose and was observed in the majority of cats administered ZORBIUM. Elevated temperatures ranged from 102.6 °F to 104.5 °F. The highest temperatures occurred at 2 hours after the first dose, gradually decreasing by 24 hours. By 3 days after dose administration, body temperatures in cats administered ZORBIUM had returned to levels observed in the vehicle control group. After the second and third doses (days 4 and 8), mean temperatures in all ZORBIUM groups were again higher than in the vehicle control group, but not higher than the normal reference range.

Constipation was recorded for 20 cats (1 vehicle control; 3 in 1X; 4 in 2X; 6 in 3X groups) after the first dose. The constipation was mild and transient. Three cats (2 in the 1X group and 1 in the 3X group) were administered a laxative. ZORBIUM had no clinically significant effects on heart rate or respiratory rate. There were no clinically relevant changes to serum chemistry, hematology, or urinalysis outcomes. Histopathology evaluations revealed mild inflammation of skin at the application site.

Seven Day Target Animal Safety Study: In a 7-day laboratory study, ZORBIUM was administered once topically to the dorsal cervical area of 24 healthy adult domestic cats (6 cats/group) at 0 mg/kg (0X; vehicle control), 3.3 (0.5X), 10 (1.5X), or 30 mg/kg (4.5X the maximal dose of 6.7 mg/kg). Cats were observed for 7 days after the single dose. Clinical results were similar to the 12-day margin of safety study, even at the higher dose of 30 mg/kg, except for transient increases in heart rate in the ZORBIUM groups compared to the vehicle control group. Mean heart rates in ZORBIUM groups were higher than in the vehicle control group from 2 hours through approximately 48 hours after dose administration. Tachycardia (>240 beats per minute) occurred in two cats in the 0.5X group and two cats in the 4.5X group for at least one timepoint after dose administration. The highest heart rate was 260 (in the 0.5X group) and no dose relationship was evident. Dose-independent euphoria, mild dysphoria, and mydriasis were noted in the ZORBIUM groups. Mild constipation and/or abdominal distension were observed with ZORBIUM administration. Transient increases in plasma chloride and sodium concentrations in the ZORBIUM groups compared to vehicle control group indicated mild dehydration.

Cardiovascular Safety Study: In a 12-day cardiovascular laboratory safety study, ZORBIUM was administered to 8 healthy adult cats (4 cats per group) at 0 mg/kg (vehicle control) and 6.7 mg/kg (1X) as a topical application to the dorsal cervical region every 4 days for a total of 3 doses. Continuous, direct physiological monitoring (telemetry) was conducted from 2 hours prior to the first dose through 4 days following the third (final) dose. Body temperature increases averaged <0.4 ºF in ZORBIUM group cats over vehicle control cats. In the vehicle control group, 102.6 °F was the maximum temperature, observed at 93 hours after the first dose. In the ZORBIUM group, 103.4 °F was the maximum temperature, observed at 20 hours after the first dose. Heart rate (HR) increased an average of 15.2 beats/minute in the ZORBIUM group cats compared to vehicle control cats. The maximum heart rate in the ZORBIUM group reached 231 beats/minute. In the vehicle control group, the maximum heart rate was 219 beats/minute. Blood pressure (arterial systolic, diastolic, and mean) in the ZORBIUM group cats was not significantly different from the vehicle control cats. There were no clinically significant effects of ZORBIUM on qualitative electrocardiogram results.

STORAGE INFORMATION:

Store at or below 25 °C (77 °F). Excursions permitted to 30 °C (86 °F).

HOW SUPPLIED:

ZORBIUM is available in applicator tubes that deliver a dose volume of 0.4 mL or 1 mL (20 mg/mL buprenorphine) in multi-packs of 10 tubes.

Approved by FDA under NADA # 141-547

Manufactured for:
Elanco US Inc.
Greenfield, IN 46140 USA

Rev. Date 02/2022

Shelter Pricing –Companion Animal

Norbrook Brands Available for Special Pricing:

- Enroflox® (enrofloxacin) Chewable Tablets
- Enroflox® (enrofloxacin) 2.27% Injection for Dogs
- Carprieve® (carprofen) Caplets
- Carprieve® (carprofen) Injection
- Loxicom® (meloxicam) Oral Suspension
- Midamox™ (imidacloprid + moxidectin) Topical
- Selarid® (selamectin) Topical

Effective Dates: August 1, 2023 –July 31, 2024

Program Details:

- To qualify the Shelter must have proof of 501(c)(3) status.
- *Shelters may take advantage of any Free Goods promotions offered by Norbrook; in addition to the 10% discount.*
- Norbrook reserves the right to change or cancel the program at any time; including price changes reflective of overall brand price increases/decreases.

Norbrook, Inc.
9401 Indian Creek Parkway, Suite 680 • Overland Park, KS 66210
Phone: 913-599-5777 • Toll Free: 866-591-5777

Norbrook Shelter Pricing

(August 1, 2023 - July 31, 2024)

Product Description	Shelter Price/Unit
Carprieve Caplets 25mg x 30ct	$9.16
Carprieve Caplets 25mg x 60ct	$14.89
Carprieve Caplets 25mg x 180ct	$44.49
Carprieve Caplets 75mg x 30ct	$11.03
Carprieve Caplets 75mg x 60ct	$18.53
Carprieve Caplets 75mg x 180ct	$55.01
Carprieve Caplets 100mg x 30ct	$13.64
Carprieve Caplets 100mg x 60ct	$22.82
Carprieve Caplets 100mg x 180ct	$67.31
Carprieve Injection - 20ml	$57.78
Carprieve Injection – 50ml	$137.25
Loxicom 1.5mg/mL Oral Solution - 10mL	$11.33
Loxicom 1.5mg/mL Oral Solution - 32mL	$22.33
Loxicom 1.5mg/mL Oral Solution - 100mL	$47.65
Loxicom 1.5mg/mL Oral Solution - 2 x 100mL	$85.60
Loxicom 5 mg/mL Injection - 10mL	$60.28
Loxicom 5 mg/mL Injection - 20mL	$112.19
Enroflox Chewable Tablets 22.7mg x 50ct	$21.55
Enroflox Chewable Tablets 22.7mg x 200ct	$72.77
Enroflox Chewable Tablets 68mg x 50ct	$54.18
Enroflox Chewable Tablets 68mg x 200ct	$185.92
Enroflox Chewable Tablets 136mg x 50ct	$97.92
Enroflox Chewable Tablets 136mg x 200ct	$326.40
Enroflox Injection for Dogs 2.27% - 20mL	$24.98
Enroflox Injection for Dogs 2.27% - 50mL	$59.31
Enroflox Injection for Dogs 2.27% - 100mL	$112.68
Selarid (selamectin) 0.25 mL - 3 pack (Puppy/Kitten)	$20.75
Selarid (selamectin) 0.75 mL - 6 pack (Cat 5.1-15 lbs.)	$44.07
Selarid (selamectin) 1.0 mL - 6 pack (Cat 15.1-22 lbs.)	$45.14
Selarid (selamectin) 0.25 mL - 6 pack (Dog 5.1-10 lbs.)	$42.80
Selarid (selamectin) 0.5 mL - 6 pack (Dog 10.1-20 lbs.)	$44.07
Selarid (selamectin) 1.0 mL - 6 pack (Dog 20.1-40 lbs.)	$46.27
Selarid (selamectin) 2.0 mL - 6 pack (Dog 40.1-85 lbs.)	$46.37
Midamox (imidacloprid+moxidectin) 0.23 mL - 3 pack (Kitten 2-5 lbs.)	$22.05
Midamox (imidacloprid+moxidectin) 0.4 mL - 6 pack (Cat 5.1-9 lbs.)	$51.53
Midamox (imidacloprid+moxidectin) 0.8 mL - 6 pack (Cat 9.1-18 lbs.)	$51.53
Midamox (imidacloprid+moxidectin) 0.4 mL - 6 pack (Dog 3-9 lbs.)	$55.17
Midamox (imidacloprid+moxidectin) 1.0 mL - 6 pack (Dog 9.1-20 lbs.)	$55.17
Midamox (imidacloprid+moxidectin) 2.5 mL - 6 pack (Dog 20.1-55 lbs.)	$55.17
Midamox (imidacloprid+moxidectin) 4.0 mL - 6 pack (Dog 55.1-88 lbs.)	$55.17

PIVETAL 2024
SHELTER PROGRAM

January 1 – December 31, 2024

Pivetal's Shelter Program is an exclusive offer for qualifying customers, including zoos, wildlife refuges, animal shelters, and humane societies. Discounts will be applied upon verification of 501(c)(3) qualification. No limit.

ANTIBIOTICS
10% OFF

FLUROXIN™
(enrofloxacin) FLAVORED TABLETS

21304186 Tablets 22.7 mg | 100s (Rx)
21304187 Tablets 22.7 mg | 500s (Rx)
21304188 Tablets 68 mg | 50s (Rx)
21304189 Tablets 68 mg | 250s (Rx)
21304280 Tablets 136 mg | 50s (Rx)
21304281 Tablets 136 mg | 200s (Rx)

FLUROXIN™
(enrofloxacin) INJECTION

21306485 2.27% Injection For Dogs | 20 mL (Rx)
21306486 2.27% Injection For Dogs | 50 mL (Rx)
21306487 2.27% Injection For Dogs | 100 mL (Rx)

NUTRITION
10% OFF

PROBIOTIC SUPPLEMENT

21294613 Cats | 30s
21294614 Dogs | 30s

E-COLLARS
10% OFF

BAXTER

21294629 Size 7.5
21294630 Size 10
21294631 Size 12
21294632 Size 15
21294633 Size 20
21294634 Size 25
21294635 Size 30

BAXTER CLEAR

21294637 Size 7.5
21294638 Size 10
21294639 Size 12
21294640 Size 15
21294641 Size 20
21294642 Size 25
21294643 Size 30

LOCK RITE

21294662 Size 7.5
21294663 Size 10
21294664 Size 12
21294665 Size 15
21294666 Size 20
21294667 Size 25
21294668 Size 30
21294669 Size 40

FLUID MANAGEMENT
10% OFF

WINGED INFUSION SETS

21294539 19G x 3/4", 12 Inch Tubing | Each
21294550 21G x 3/4", 12 Inch Tubing | Each
21294551 22G x 3/4", 12 Inch Tubing | Each
21294552 23G x 3/4", 12 Inch Tubing | Each
21294553 25G x 3/4", 12 Inch Tubing | Each

IV CATHETERS

21294534 18G x 1-1/4" | Each
21294535 20G x 1" | Each
21294536 20G x 1-1/4" | Each
21294537 22G x 1" | Each
21294538 24G x 3/4" | Each

IV ADMINISTRATION SETS



21294499 10 Drop, 2 Y-site, 103 Inch, Series B | Each
21294498 10 Drop, Y-site, 103 Inch, Series B | Each
21294494 15 Drop, 2 Y-site, 103 Inch, Series A | Each
21294493 15 Drop, Y-site, 80 Inch, Series A | Each
21294497 15 Drop, Y-site, 80 Inch, Series B | Each
21294492 60 Drop, Y-site, 70 Inch, Series A | Each
21294496 60 Drop, Y-site, 70 Inch, Series B | Each
21294583 Needle-free, 10 Drop, Y-site, 103 Inch, Series B | Each
21294896 Needle-free, 10 Drop, Y-site, 78 Inch, Series B | Each
21294582 Needle-free, 15 Drop, Y-site, 103 Inch, Series A | Each
21294895 Needle-free, 15 Drop, Y-site, 78 Inch, Series A | Each
21289566 Secondary IV Administration Set, 15 Drop, 35 Inch | Each

INSULIN SYRINGES

21295149 U40, 0.3 cc, 29G x 1/2" | 100s
21295161 U40, 0.5 cc, 29G x 1/2" | 100s
21295160 U40, 1 cc, 29G x 1/2" | 100s
21295148 U100, 0.3 cc, 29G x 1/2" | 100s
21295061 U100, 0.5 cc, 29G x 1/2" | 100s

IV EXTENSION SETS

21294558 Extension Set, 2 Y-site, Rotating Luer, 32 Inch | Each
21289555 Extension Set, 2 Y-site, Rotating Luer, 42 Inch | Each
21294556 Extension Set, Luer Slip, 30 Inch | Each
21294557 Extension Set, Rotating Luer, 30 Inch | Each
21289567 Extension Set, Y-site, Rotating Luer, 30 Inch | Each
21294580 Needle-free Extension Set, Y-site, Rotating Luer, 30 Inch | Each
21294581 Needle-free Extension Set, 2 Y-site, Rotating Luer, 42 Inch | Each

MALE ADAPTERS

21294554 Male Adapter, Luer Lock
21294587 Male Adapter, Luer Slip
21293555 Needle-free Male Adapter, Luer Lock

T-PORTS

21293558 T-connector, Macrobore, Luer Lock, 7 Inch
21293557 T-connector, Microbore, Luer Lock, 5 Inch
21293556 T-connector, Microbore, Luer Slip, 5 Inch
21293559 Needle-free T-connector, Microbore, Luer Lock, 7 Inch
21294555 Needle-free T-connector, Microbore, Luer Slip, 7 Inch

HYPODERMIC NEEDLES

21295184 Polypropylene Hub, 18G x 1" Regular Bevel, Rigid Pack | 100s
21295183 Polypropylene Hub, 18G x 1 1/2" Regular Bevel, Rigid Pack | 100s
21295179 Polypropylene Hub, 20G x 1" Regular Bevel, Rigid Pack | 100s
21295178 Polypropylene Hub, 20G x 1-1/2" Regular Bevel, Rigid Pack | 100s
21295181 Polypropylene Hub, 20G x 3/4" Regular Bevel, Rigid Pack | 100s
21295176 Polypropylene Hub, 22G x 1" Regular Bevel, Rigid Pack | 100s
21295177 Polypropylene Hub, 22G x 3/4" Regular Bevel, Rigid Pack | 100s
21295175 Polypropylene Hub, 25G x 5/8" Regular Bevel, Rigid Pack | 100s

BIFUSE SET

21294586 Needle-free Bifuse Set, Microbore, Luer Lock, 7 Inch | Each

WHITE GOODS
10% OFF

COHESIVE WRAP

21305560 2 Inch, Assorted | 36s
21305561 2 Inch, Neon Assorted | 36s
21305562 2 Inch, No-chew Assorted | 36s

COTTON TIPPED APPLICATOR

21295054 Cotton Tipped Applicators, 6 Inch | 1000s

GAUZE BANDAGE

21295008 Gauze Bandage Rolls, Non-sterile, 2-ply, 1 Inch | 12s
21295009 Gauze Bandage Rolls, Non-sterile, 2-ply, 2 Inch | 12s
21295030 Gauze Bandage Rolls, Non-sterile, 2-ply, 3 Inch | 12s
21295031 Gauze Bandage Rolls, Non-sterile, 2-ply, 4 Inch | 12s

CONFORMING STRETCH GAUZE BANDAGE

21295032 Conforming Stretch Gauze Bandage, Non-sterile, 1-ply, 2 Inch x 4 Yards | 12s
21295033 Conforming Stretch Gauze Bandage, Non-sterile, 1-ply, 3 Inch x 4 Yards | 12s
21295034 Conforming Stretch Gauze Bandage, Non-sterile, 1-ply, 4 Inch x 4 Yards | 12s

ECONOMY GAUZE SPONGE

21295005 Economy Gauze Sponge, Non-sterile, 12-ply, 3"x 3" | 200s
21295006 Economy Gauze Sponge, Non-sterile, 12-ply, 4"x 4" | 200s

GAUZE SPONGE

21295037 Non-woven Gauze Sponge, Non-sterile, 4-ply, 2"x 2" | 200s
21295039 Non-woven Gauze Sponge, Non-sterile, 4-ply, 3"x 3" | 200s
21295051 Non-woven Gauze Sponge, Non-sterile, 4-ply, 4"x 4" | 200s
21295035 Woven Gauze Sponge, Non-sterile, 12-ply, 2"x 2" | 200s
21295038 Woven Gauze Sponge, Non-sterile, 12-ply, 3"x 3" | 200s
21295050 Woven Gauze Sponge, Non-sterile, 12-ply, 4"x 4" | 200s
21295052 Woven Gauze Sponge, Non-sterile, 8-ply, 4"x 4" | 200s

ELASTIC TAPE

21300869 Elastic Tape 2 Inch x 5 Yards | 6s
21300930 Elastic Tape 3 Inch x 5 Yards | 4s
21300931 Elastic Tape 4 Inch x 5 Yards | 6s

POROUS TAPE

21300865 Porous Tape 0.5 Inch x 10 Yards | 24s
21300866 Porous Tape 1 Inch x 10 Yards | 12s
21300868 Porous Tape 2 Inch x 10 Yards | 6s

NSAIDS
15% OFF

ALLOXATE™
(meloxicam) INJECTION

21294589 Injection 5 mg | 10 mL (Rx)
21294590 Injection 5 mg | 20 mL (Rx)

COXIBA®
(deracoxib) CHEWABLE TABLETS

21306859 Chewable Tablets 12 mg | 30s (Rx)
21306860 Chewable Tablets 12 mg | 90s (Rx)
21306861 Chewable Tablets 25 mg | 30s (Rx)
21306862 Chewable Tablets 25 mg | 90s (Rx)
21306863 Chewable Tablets 75 mg | 30s (Rx)
21306864 Chewable Tablets 75 mg | 90s (Rx)
21306865 Chewable Tablets 100 mg | 30s (Rx)
21306866 Chewable Tablets 100 mg | 90s (Rx)

LEVAFEN™
(carprofen) CAPLETS

21295236 Caplets 25 mg | 60s (Rx)
21295237 Caplets 25 mg | 180s (Rx)
21295238 Caplets 75 mg | 60s (Rx)
21295239 Caplets 75 mg | 180s (Rx)
21295310 Caplets 100 mg | 60s (Rx)
21295311 Caplets 100 mg | 180s (Rx)

LEVAFEN™
(carprofen) CHEWABLE TABLETS

21306850 Chewable Tablets 25 mg | 30s (Rx)
21306851 Chewable Tablets 25 mg | 60s (Rx)
21306852 Chewable Tablets 25 mg | 180s (Rx)
21306853 Chewable Tablets 75 mg | 30s (Rx)
21306854 Chewable Tablets 75 mg | 60s (Rx)
21306855 Chewable Tablets 75 mg | 180s (Rx)
21306856 Chewable Tablets 100 mg | 30s (Rx)
21306857 Chewable Tablets 100 mg | 60s (Rx)
21306858 Chewable Tablets 100 mg | 180s (Rx)

LEVAFEN™
(carprofen) INJECTION

21294547 Injection 50 mg | 20 mL (Rx)
21294548 Injection 50 mg | 50 mL (Rx)

ANALGESICS
10% OFF

DEXASED™
(dexmedetomidine hydrochloride) INJECTION

78949297 Injection 0.5 mg/mL | 10 mL (Rx)

ANESTHETICS
10% OFF

REVERTASED
(atipamazole) INJECTION

78949389 Injection 5.0 mg/mL | 10 mL (Rx)

PIVETAL SHELTER PROGRAM RULES

Offer applies to practicing veterinarians only.
Pivetal reserves the right to change, cancel, or refuse this program at any time. Cannot be combined with any other discounts, promotions, or programs.

Offer valid January 1 - December 31, 2024.

STAY IN TOUCH
WITH PIVETAL

Follow us on Facebook and Instagram for product information, giveaways and more. **Scan today!**

sentrx™ Animal Care

Ophthalmologist and Animal Welfare Program

Veterinary accounts such as shelters, educational entities, for-profit clinics with a board certified veterinary ophthalmologist on staff

Save 10% off six (6) bottles and 25% off of eighteen (18) or more bottles of BioHAnce™ products (can be a mix or match of all Sentrx BioHAnce™ products which includes Ocunovis Procare BioHAnce Gel Eye Drops and Oculenis BioHAnce Ocular Repair Gel)

Save 10% off the purchase of six (6) or more Eye Lube Pro.

Learn more about Sentrx™ products at sentrxanimalcare.com/learnmore/

Terms and Conditions

This promotion applies to products on the same order and is restricted to Veterinary accounts with a full-time Veterinarian on staff, such as shelters, animal care/control agencies and other not-for-profit organizations (NFP Account). This includes government/military institutions, as well as, educational entities (e.g. colleges,universities, technical schools, etc.). For profit veterinary practices/ clinics ineligible unless a verified, board certified veterinary ophthalmologist is on staff full time. Veterinary partner pharmacies, accounts with direct-to-consumer sales via internet, website, catalog or other over-the-counter channels are ineligible. Customers participating in this program are not eligible for any other promotions or rebates on products covered by this agreement. Customers must show proof of 501(c)(3) status upon request. Sentrx Animal Care reserves the right to vary the terms and conditions of these promotions or cancel these promotions at any time without notice. Program valid through December 31, 2024.

ocunovis procare
BioHAnce™ Gel Eye Drops with Amino Acids

Lubrication designed to last longer

oculenis
BioHAnce™ Ocular Repair Gel

Corneal repair gel

eye lube pro

Bulk lubrication at a value price

Sentrx Product Name	Key Ingredients	Use and Support
Ocunovis™ ProCare BioHAnce™ Gel Eye Drops with Amino Acids	.40% Cross-linked HA	• Lubrication for dry eye with as little as 2 applications a day • Shown to help stabilize tear film(1) • Lasts 2-5x longer than traditional artificial tears (2,3)
Oculenis™ BioHAnce™ Ocular Repair Gel	.75% Cross-linked HA	• Supports 50% faster healing of damaged cornea (4) • Unlike serum, shown not to bind to antibiotics(5)

BioHAnce™ technology uses advanced bioengineering to create a molecular matrix of cross-linked hyaluronic acid. Cross-linked HA creates a cellular scaffolding with unique physical and chemical properties that extend lubrication 2-5x longer than traditional HA drops(2,3) and accelerates the bodies own healing process by up to 50%(4). Cross-linking creates a more viscous lubricant at a lower concentration with muco-adhesive properties that extends duration in a way traditional products cant. HA that is cross-linked also creates a sheer thinning property where the gel rebounds during blinking and does not blur or get discarded from the ocular surface like traditional lubricants. Once HA has been cross-linked, it changes the chemical and physical properties. Thus, you can't compare the concentration of an HA product to the concentration of a cross-linked product.

Eye Lube Pro Lubricating Gel	Carbomer and . 30% traditional HA	• Just like other traditional eye lubes, product may need to be applied more often • HA and carbomer formulation offers bulk lubrication at a value price

sentrx Animal Care **Sentrxanimalcare.com/learnmore** **@sentrxanimalcare**

1.EVALUATION OF TOPICALLY APPLIED CROSS-LINKED HYALURONIC ACID (REMEND®) ON THEOCULAR SURFACE OF CLINICALLY HEALTHY DOGS (CE Plummer, 1 BC Martins, 2 C Bolch, 3 PS Martinez, 1 Carbia BE, 1) College of Veterinary Medicine, University of Florida; 1 School of Veterinary Medicine, Univer sity of California- Davis; 2 Institute for Vision Research, University of Florida; 3

2.FLUOROMETRIC EVALUATION OF CROSS-LINKED VS LINEAR HYALURONIC ACID EYE LUBRICANTS (F Montiani-Ferreira, 2 SK Atzet, 1 AD Fankhauser, 1 EK Behan, 1 DJ Haeussler, 3) SentrX Animal Care;1 Veterinary Medicine Department, Federal University of Paraná; 2 Animal Eye Institute; 3

3. PRECORNEAL RETENTION TIME OF OCULAR LUBRICANTS IN DOGS (L Bedos, 1 RA Allbaugh, 1MM Roy, 1 MA Kubai, 1 L Sebbag 1,2) Iowa State University College of Veterinary Medicine 1; Koret School of Veterinary Medicine, The Hebrew University of Jerusalem 2.

4.Williams DL, Wirostko BM,Gum G, Mann BK. Topical cross-linked HA-based hydrogel accelerates closure of corneal epithelial defects and repair of stromal ulceration in companion animals. Invest Ophthalmol Vis Sci. 2017;58:4616–4622. DOI:10.1167/iovs.16-20848

5.EVALUATION OF CROSSLINKED HYALURONIC ACID GEL DROPS AND THERAPEUTIC COMBINATIONS FOR OPHTHALMIC INFECTIONS (SK Atzet, 1 AD Fankhauser, 1 EK Behan, 1 BK Mann, 1) SentrX Animal Care;1

BUY 4, GET 1 FREE*

ANIMAL WELFARE PROMO

Good for any Vetoquinol companion animal product, *except for Imoxi® Topical Solution (imidacloprid + moxidectin), which is buy 3, get 1 free.*

WHO QUALIFIES?

Any organization that can exhibit nonprofit status; all 501(c)(3) organizations such as animal shelters, humane societies, zoos, and wildlife refuges.

ENROLL YOUR ORGANIZATION

Scan this QRCode to enroll.

OFFER VALID FOR PURCHASES DATED
January 1, 2024 — December 31, 2024

DETAILS

- Good for any Vetoquinol companion animal product*
- Cannot be combined with any other Vetoquinol promo offer
- Kind for kind, no mix and match**
- All purchased and free products MUST be on the same invoice
- Free and purchased product ship together

DISTRIBUTORS

- Shelter/Humane Society form must be completed prior to ordering: http://vtq.io/welfare-promotion
- All organizations submitting promotional orders are subject to Vetoquinol approval of non-profit status.
- Vetoquinol will not accept returns on any free product obtained through promotion.
- Please reference code: **WELFARE** on invoice to qualify for reimbursement, per current free goods policy.
- Free goods will be reimbursed in accordance with Vetoquinol Distributor Terms & Conditions.
- Any account that was approved in 2023 will be auto re-enrolled in this program for 2024.

* Phovia® Lamp System (462467) is excluded from this promotion. Clevor® (462253) is limited to a maximum of one free unit per order.

** Imoxi® is eligible up to 6 free total cartons across all SKUs per order; free cartons are of equal or lesser value than those purchased.

TERMS AND CONDITIONS

The Animal Welfare Program is intended for customers engaged in the rescue, adoption, and shelter of dogs and cats. Customers must demonstrate non-profit status in order to qualify. Vetoquinol reserves the right to evaluate account eligibility. Decisions with respect to eligibility are at Vetoquinol's sole discretion. Animal Welfare orders placed on a personal DVM account will not be honored. Reselling of products to other shelters, veterinary organizations or directly to consumers (via internet, OTC or otherwise) is not allowed and **will result in organization no longer being able to purchase Vetoquinol products.** Customers participating in this promotion are not eligible for any other Vetoquinol promotions or rebates, including the 2024 Clinic Partnership Agreement. Purchase of a prescription product requires a valid veterinary license on file. Vetoquinol reserves the right to cancel or modify this program at any time.

1.800.267.5707
vetoquinolusa.com

CA-22-00014 11/23

vetoquinol
ACHIEVE MORE TOGETHER

2024

VIRBAC SHELTER SAVINGS PROGRAM

Special discounts for some very special people.

At Virbac, we value the important work you do each day to rescue, heal, and care for animals in need. That's why we are offering special savings on important healthcare products to shelters like yours.

SAVE ON GREAT PRODUCTS FROM VIRBAC.

Updated pricing effective September 1, 2023. See the following product information for details. Prices subject to change at any time.

Virbac

Shaping the future of animal health

VIRBAC PRODUCT INFORMATION

See what products Virbac has to offer at a price just for you.

PRODUCT DESCRIPTION	PRODUCT #	SIZE	SUGGESTED SHELTER PRICE
ANTIBIOTICS			
AYRADIA™ (Metronidazole Oral Suspension) for Dogs	13100	30 mL	$22.13
AYRADIA™ (Metronidazole Oral Suspension) for Dogs	13101	100 mL	$46.75
CLINTABS® (clyndamycin hydrochloride) Tablets (25 mg)	902540	400 CT.	$127.68
CLINTABS® (clyndamycin hydrochloride) Tablets (75 mg)	907520	200 CT.	$165.69
CLINTABS® (clyndamycin hydrochloride) Tablets (150 mg)	915010	100 CT.	$108.08
SKIN HEALTH			
ALLERDERM® Foaming Cleanser	13500	6.76 OZ	$10.88
ALLERDERM OMEGADERM® Essential Fatty Acids Supplement CATS / SMALL DOGS	14149	4 ML / 28 CT	$12.34
ALLERDERM OMEGADERM® Essential Fatty Acids Supplement MEDIUM / LARGE DOGS	14186	8 ML / 28 CT	$16.92
ALLERGROOM® Shampoo	12208	8 OZ	$8.10
	12216	16 OZ	$13.30
ALLERMYL® (Piroctone Olamine) Shampoo	002409	8 OZ	$14.70
	002417	16 OZ	$24.62
CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED	20301	15 mL	$45.99
	20303	50 mL	$110.36
EPI-SOOTHE® Cream Rinse	001808	8 OZ	$9.25
	001816	16 OZ	$16.59
EPI-SOOTHE® Shampoo	11708	8 OZ	$7.91
	11716	16 OZ	$14.02
GENESIS® Topical Spray (0.015% triamcinolone acetonide)	410508	8 OZ	$13.93
	410500	16 OZ	$23.23
ITRAFUNGOL® (itraconazole oral solution) (10 mg/mL)	11605	52 mL	$37.46
KETOCHLOR® Shampoo (Chlorhexidine gluconate, ketoconazole)	002908	8 OZ	$13.93
	002916	16 OZ	$21.91
KERATOLUX® (Piroctone Olamine) Medicated Shampoo	002009	8 OZ	$10.22
	002017	16 OZ	$18.20
SUPPLEMENTS			
NEPHRODYL™ Synbiotic Capsules	12620	60 ct.	$38.28
REBOUND® Recuperation Formula for Cats	10851	5.1 oz	$9.94
REBOUND® Recuperation Formula for Dogs	10850	5.1 oz	$9.94
TUMIL - K® (potassium gluconate) Powder	846004	4 OZ	$29.87
TUMIL - K® (potassium gluconate) Tablets	845100	100 CT	$26.50
VETASYL® Fiber Capsules (500 mg)	VF410	100 CT.	$21.00
BEHAVIOR			
ANXITANE® (L-Theanine) Chewable Tablets - Small 50 mg	10432	30 CT	$23.85
ANXITANE® (L-Theanine) Chewable Tablets - Medium & Large 100 mg	10435	30 CT	$30.07
CLOMICALM® (clomipramine hydrochloride) - 5 mg	10506	30 CT	$27.56
CLOMICALM® (clomipramine hydrochloride) - 20 mg	10507	30 CT	$37.39
CLOMICALM® (clomipramine hydrochloride) - 80 mg	10508	30 CT	$47.22
ZENIDOG® Long-Acting Collar – Puppy/Small	10512	1	$21.68
ZENIDOG® Long-Acting Collar – Medium/Large	10513	1	$21.68
ZENIDOG® Gel Diffuser	10514	1	$15.30

VIRBAC PRODUCT INFORMATION

See what products Virbac has to offer at a price just for you.

PRODUCT DESCRIPTION	PRODUCT #	SIZE	SUGGESTED SHELTER PRICE
EAR HEALTH			
EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs	09360	10 mL	$16.63
EPIOTIC® *Advanced* Ear Cleanser	003104	4 OZ	$7.00
	003108	8 OZ	$11.38
OTOMITE PLUS® Ear Miticide	601712	.5 OZ	$8.32
DENTAL			
C.E.T. AQUADENT® FR3SH® Dental Solution	90508	250 mL	$8.75
C.E.T. AQUADENT® FR3SH® Dental Solution	90516	500 mL	$9.77
C.E.T.® Mini-Toothbrush w/ 0.4 oz (12 g) Trial-Size Packet	CET302	1 each	$4.32
C.E.T.® Cat Toothbrush w/ 0.4 oz (12 g) Trial-Size Packet	CET303	1 each	$4.42
C.E.T.® Dual-Ended Toothbrush	CET305	1 each	$3.96
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - EXTRA - SMALL	90015	45 Single CT	$30.35
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - SMALL	90016	30 Single CT	$22.74
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - MEDIUM	90017	28 Single CT	$24.44
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - LARGE	90018	24 Single CT	$22.89
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - EXTRA - SMALL	90055	30 CT	$13.94
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - SMALL	90056	30 CT	$15.59
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - MEDIUM	90057	30 CT	$17.95
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - LARGE	90058	30 CT	$20.62
C.E.T.® VEGGIEDENT® ZEN Tartar Control Chews for Dogs - EXTRA - SMALL	90075	30 CT	$15.73
C.E.T.® VEGGIEDENT® ZEN Tartar Control Chews for Dogs - SMALL	90076	30 CT	$17.65
C.E.T.® VEGGIEDENT® ZEN Tartar Control Chews for Dogs - MEDIUM	90077	30 CT	$20.43
C.E.T.® VEGGIEDENT® ZEN Tartar Control Chews for Dogs - LARGE	90078	30 CT	$23.20
C.E.T.® VEGGIEDENT® FLEX Tartar Control Chews for Dogs - EXTRA - SMALL	90085	30 CT	$16.10
C.E.T.® VEGGIEDENT® FLEX Tartar Control Chews for Dogs - SMALL	90086	30 CT	$18.00
C.E.T.® VEGGIEDENT® FLEX Tartar Control Chews for Dogs - MEDIUM	90087	30 CT	$20.83
C.E.T.® VEGGIEDENT® FLEX Tartar Control Chews for Dogs - LARGE	90088	30 CT	$23.66
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - EXTRA SMALL	90601	8.4 oz.	$8.61
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - SMALL	90603	8.5 oz.	$10.78
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - MEDIUM	90605	12.8 oz.	$14.03
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - LARGE	90607	1.13 lbs.	$17.27
C.E.T.® Enzymatic Toothpaste - BEEF	CET201	70 gm	$6.79
C.E.T.® Enzymatic Toothpaste - SEAFOOD	CET202	70 gm	$6.79
C.E.T.® Enzymatic Toothpaste - MALT	CET102	70 gm	$6.79
C.E.T.® Enzymatic Toothpaste - POULTRY	CET101	70 gm	$6.79
C.E.T.® Enzymatic Toothpaste - VANILLA - MINT	CET103	70 gm	$6.79
C.E.T.® Enzymatic Toothpaste - Trial Packet Dispenser	CET002	12 gm / 25 CT	$20.83
C.E.T.® Fingerbrush with 12 gm Trial Packet	CET301	1 EACH	$4.11
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - EXTRA SMALL	90612	8.4 oz.	$10.21
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - SMALL	90614	8.5 oz.	$13.23
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - MEDIUM	90616	12.8 oz.	$20.33
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - LARGE	90618	1.13 lbs.	$24.95
C.E.T.® IntelliDent® Cat Bites	90700	90 BITES	$5.62
C.E.T.® Oral Hygiene Kits for Cats with 70 gm - SEAFOOD	CET402	1 EACH	$8.69
C.E.T.® Oral Hygiene Kits for Dogs with 70 gm - POULTRY	CET401	1 EACH	$8.69
C.E.T.® Pet Toothbrush	CET304	1 EACH	$3.96
C.E.T.® Pet Toothbrush Bulk Dispenser	CET350	24 ct.	$63.54

VIRBAC PRODUCT INFORMATION

See what products Virbac has to offer at a price just for you.

PRODUCT DESCRIPTION	PRODUCT #	SIZE	SUGGESTED SHELTER PRICE
HEARTWORM			
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Toy	50102	10 BOXES 6 DOSES	$233.31
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Small	50104	10 BOXES 6 DOSES	$233.31
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Medium	50106	10 BOXES 6 DOSES	$285.86
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Large	50108	10 BOXES 6 DOSES	$337.42
IVERHART PLUS® (ivermectin/pyrantel) *Flavored Chewables* - Display - Small	0170DS	10 BOXES 6 DOSES	$145.75
IVERHART PLUS® (ivermectin/pyrantel) *Flavored Chewables* - Display - Medium	0170DM	10 BOXES 6 DOSES	$195.25
IVERHART PLUS® (ivermectin/pyrantel) *Flavored Chewables* - Display - Large	0170DL	10 BOXES 6 DOSES	$253.21
MILBEHART® (milbemycin oxime) Flavored Tablets for Dogs - 2 - 10 lbs Display	31024	10 BOXES 6 DOSES	$177.26
MILBEHART® (milbemycin oxime) Flavored Tablets for Dogs - 11 - 25 lbs / Cats 1.5 - 6 lbs - Display	31025	10 BOXES 6 DOSES	$179.48
MILBEHART® (milbemycin oxime) Flavored Tablets for Dogs - 26 - 50 lbs / Cats 6.1 - 12 lbs - Display	31026	10 BOXES 6 DOSES	$229.96
MILBEHART® (milbemycin oxime) Flavored Tablets for Dogs - 51 - 100 lbs / Cats 12.1 - 25 lbs - Display	31027	10 BOXES 6 DOSES	$280.39
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution 3-9 lbs- Display	51115	10 BOXES 3 DOSES	$261.08
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution 9.1-20 lbs- Display	51116	10 BOXES 3 DOSES	$261.08
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution 20.1-55 lbs- Display	51117	10 BOXES 3 DOSES	$261.08
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution 55.1- 88 lbs- Display	51118	10 BOXES 3 DOSES	$261.08
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution 88.1-110 lbs	51119	5 BOXES 3 DOSES	$130.53
PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution 2-5 lbs - Display	51120	10 BOXES 3 DOSES	$221.09
PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution 5.1-9 lbs - Display	51121	10 BOXES 3 DOSES	$258.39
PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution 9.1-18 lbs - Display	51122	10 BOXES 3 DOSES	$258.39
SENERGY® (selamectin) Display - Kitten and Puppy	50090	10 BOXES 3 DOSES	$235.63
SENERGY® (selamectin) for Cats - Display - 5.1 to 15 lbs	50095	10 BOXES 3 DOSES	$271.43
SENERGY® (selamectin) for Cats - Display - 15.1 to 22 lbs	50097	10 BOXES 3 DOSES	$278.28
SENERGY® (selamectin) for Dogs - Display - Toy	50005	10 BOXES 3 DOSES	$263.70
SENERGY® (selamectin) for Dogs - Display - Small	50010	10 BOXES 3 DOSES	$271.74
SENERGY® (selamectin) for Dogs - Display - Medium	50020	10 BOXES 3 DOSES	$285.34
SENERGY® (selamectin) for Dogs - Display - Large	50040	10 BOXES 3 DOSES	$285.69
SENERGY® (selamectin) for Dogs - Display - Extra Large	50085	10 BOXES 3 DOSES	$373.69
Mobility			
MOVODYL™ Chewable Tablets (carprofen) (25 mg)	10021	60	$19.26
MOVODYL™ Chewable Tablets (carprofen) (75 mg)	10022	60	$23.83
MOVODYL™ Chewable Tablets (carprofen) (100 mg)	10023	60	$29.92
MOVODYL™ Chewable Tablets (carprofen) (25 mg)	10024	180	$54.74
MOVODYL™ Chewable Tablets (carprofen) (75 mg)	10025	180	$68.37
MOVODYL™ Chewable Tablets (carprofen) (100 mg)	10026	180	$86.63
MOVOFLEX® Advanced Soft Chews - SMALL (2 gm)	10418	60 CT	$31.71
MOVOFLEX® Advanced Soft Chews - MEDIUM (4 gm)	10419	60 CT	$36.79
MOVOFLEX® Advanced Soft Chews - LARGE (6 gm)	10420	60 CT	$42.14

VIRBAC PRODUCT INFORMATION

See what products Virbac has to offer at a price just for you.

PRODUCT DESCRIPTION	PRODUCT #	SIZE	SUGGESTED SHELTER PRICE
PARASITICIDES			
EFFIPRO® PLUS Topical Solution for Cats	60463	10 BOXES 3 DOSES	$215.28
EFFIPRO® PLUS Topical Solution for Dogs - SMALL	60473	10 BOXES 3 DOSES	$227.49
EFFIPRO® PLUS Topical Solution for Dogs - MEDIUM	60483	10 BOXES 3 DOSES	$227.49
EFFIPRO® PLUS Topical Solution for Dogs - LARGE	60503	10 BOXES 3 DOSES	$227.49
EFFIPRO® PLUS Topical Solution for Dogs - EXTRA - LARGE	60513	10 BOXES 3 DOSES	$227.49
EFFITIX® PLUS Topical Solution for Dogs - TOY	60520	10 BOXES 3 DOSES	$241.14
EFFITIX® PLUS Topical Solution for Dogs - SMALL	60522	10 BOXES 3 DOSES	$241.14
EFFITIX® PLUS Topical Solution for Dogs - MEDIUM	60524	10 BOXES 3 DOSES	$241.14
EFFITIX® PLUS Topical Solution for Dogs - LARGE	60526	10 BOXES 3 DOSES	$241.14
EFFITIX® PLUS Topical Solution for Dogs - EXTRA - LARGE	60528	10 BOXES 3 DOSES	$241.14
VIRBANTEL® (Pyrantel Pamoate / Praziquantel) Flavored Chewables SMALL DOGS & PUPPIES	54030	50 CT.	$173.54
VIRBANTEL® (Pyrantel Pamoate / Praziquantel) Flavored Chewables MEDIUM & LARGE DOGS	51114	50 CT.	$432.98
IN CLINIC USE			
EUTHASOL® (pentobarbital sodium and phenytoin sodium) Euthanasia Solution	710101	100 mL	$65.05
SUPRELORIN® F (deslorelin acetate) Implant (4.7 mg)	44402	2 ct	$230.18
	44405	5 ct	$517.03
Zoletil™ for Injection (tiletamine and zolazepam for injection)	71805	100 mL	$52.10

Virbac

Shaping the future of animal health